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ABSTRACT  
Biomarkers of Exposure to Foodborne and Environmental Carcinogens: Enterosorbent 
Intervention in a High Risk Population. (August 2010) 
Natalie Malek Johnson, B.S., Texas A&M University  
Chair of Advisory Committee: Dr. Timothy D. Phillips 
 
 
The need to assess human exposures to foodborne and environmental 
carcinogens, particularly in populations at high risk for cancer and disease, has led to the 
development of chemical-specific biomarkers. Sensitive biomarkers for aflatoxin and 
polycyclic aromatic hydrocarbons (PAHs) have been useful in providing information on 
population exposure and reducing associated public health impacts. Aflatoxins are 
fungal metabolites found in a variety of foods. Among these toxins, aflatoxin B1 (AFB1) 
is the most predominant and hepatocarcinogenic. Acutely, AFB1 can cause disease and 
death, necessitating safe and effective intervention strategies. Inclusion of NovaSil (NS) 
clay in the diet represents a practical, sustainable approach. NS has been shown to 
prevent aflatoxicosis in multiple animal species by binding aflatoxins in the 
gastrointestinal tract, reducing toxin bioavailability. Co-exposure to PAHs, hazardous 
environmental contaminants, has been shown to increase the risk for hepatocellular 
carcinoma (HCC). Therefore, objectives of this research were to utilize biomarkers to 
assess aflatoxin and PAH exposures in susceptible populations in Ghana and the U.S. 
and to evaluate the safety and efficacy of NS intervention in Ghana (a population at risk 
for aflatoxicosis).           
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After 3-month intervention with 3.0g NS/day, median aflatoxin M1 (an AFB1 
metabolite) was significantly reduced (up to 58%) compared to the placebo group. 
Furthermore, no significant differences were found in levels of nutrient minerals 
between NS and placebo groups at baseline and 3-months suggesting NS can be used to 
effectively sorb AFB1 without affecting serum concentrations of important minerals. 
PAH biomarker results showed participants in Ghana were significantly exposed to high 
levels of PAHs based on the presence of 1-hydroxypyrene (1-OHP) in the majority of 
urines (98.9%). NS treatment had no effect on 1-OHP levels, further confirming the 
preferential binding of aflatoxins by NS. U.S. population data from a Hispanic 
community in Texas with an elevated incidence of HCC demonstrated a lower 
percentage and level of aflatoxin and PAH biomarkers. Aflatoxin M1 excretion, 
however, was associated with increased consumption of certain foods prone to aflatoxin 
contamination; thus, some individuals may be more vulnerable to exposure and 
associated interactions that increase the risk for HCC (e.g., PAHs or hepatitis infection).  
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I. INTRODUCTION 
 
 In the past century, great strides have been made in the understanding of 
chemical carcinogenesis, expanding the field from a basic knowledge that chemicals 
were able to cause cancer to the development of technologies to assess human exposures 
and study molecular pathways (Loeb and Harris 2008). Much of what we know today 
can be attributed to initial research findings from epidemiological studies and basic 
research focusing on two groups of hazardous contaminants known as aflatoxins (AFs) 
and polycyclic aromatic hydrocarbons (PAHs). For instance, Yamagiwa and Ichikawa 
first experimentally induced cancer by applying coal tar to rabbits, confirming Pott’s 
past observation of elevated cancer in chimney sweeps occupationally exposed to coal 
tar (Pott 1775; Yamagiwa and Ichikawa 1918). Within the next fifteen years, scientists 
identified PAHs as the carcinogenic material in coal tar and isolated benzo[a]pyrene, a 
model carcinogenic PAH (Kennaway 1930; Cook et al. 1933). In the 1960s, aflatoxin B1 
(AFB1) was shown to be carcinogenic in rats (Barnes and Butler 1964). Following a 
compilation of model laboratory and epidemiology studies AFB1 was established as a 
group 1 carcinogen (carcinogenic to humans) (IARC 1993). The vast amount of research 
on AFs and weight of evidence largely based on human exposure science makes AF a 
‘template’ for environmental carcinogen research (Eaton and Groopman 1994).  
1Overall, advancements in chemical carcinogenesis spurred the development of 
chemical-specific biomarkers, giving scientists the ability to assess human exposures to 
                                                 
1This dissertation follows the style of Food Additives and Contaminants.  
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important foodborne/environmental carcinogens such as AFs and PAHs. Importantly, 
biomarkers can be used to identify populations at risk for exposures. Often, the incidence 
and impact of exposures are elevated in developing countries and underserved rural or 
metropolitan communities. For instance, people living in poverty are most likely to 
consume AF-contaminated foods, and therefore suffer the most severe effects, including 
disease and even death following acute exposure (Lewis et al. 2005). AF contamination 
in food products constitutes a serious burden in the developing world where a lack of 
untainted food supplies and poverty present a major and persistent challenge (McAlpin 
et al. 2002; Shephard 2003). In a world where the population of undernourished people 
surpasses one billion and an uncountable number of individuals daily face food 
insecurity (Fedoroff et al. 2010), detoxification strategies or approaches to remedy 
adverse effects from exposure to contaminated foods is of critical necessity. 
Furthermore, interactions with other environmental contaminants or biological factors 
have been shown to increase individual vulnerability to AF exposure. A classic example 
is the synergistic interaction between hepatitis B virus and AFB1 in the development of 
hepatocellular carcinoma (HCC) (Ross et al. 1992; Henry et al. 2002). Epidemiological 
evidence has also suggested that concurrent exposure to additional environmental 
carcinogens, for example PAHs, can increase the risk of HCC development (Wu et al. 
2007). While the amount and source of environmental PAH exposure varies widely from 
country to country, developing countries have been shown to account for the higher 
percentages of PAH emissions, for instance in the case of benzo[a]pyrene (Zhang and 
Tao 2008). Thus, the implementation of biomonitoring in populations at high risk for 
 3
cancer and disease may play an important role in providing information to help reduce 
the negative public health impacts of exposures. 
1.1 Occurrence of aflatoxins 
In the past five decades, over 8,500 articles have been published describing the 
occurrence and effects of aflatoxins (AFs). In turn, AFs have become one of the most 
well-known classes of mycotoxins, secondary metabolites of fungal growth. AF-
contamination has had a major impact on food and feed industries worldwide 
presumably even before the original isolation of AF in the 1960s as the etiologic factor 
associated with turkey ‘X’ disease (Blount 1961). AFs are produced primarily by the 
fungi Aspergillus flavus and Aspergillus parasiticus (Busby and Wogan 1984; Kurtzman 
et al. 1987). They have been characterized as unavoidable contaminants in a variety of 
commodities, mainly grain and nut crops. These most notably include maize, peanuts, 
cottonseed, and tree nuts (CAST 2003). AF production can occur in the field and in 
storage. Pre-harvest fungal contamination is influenced primarily by temperature and 
moisture and is favored when growth conditions range between 24 – 35ºC at moisture 
contents between 12 – 20% (Wilson and Payne 1994). Additional factors that increase 
crop susceptibility include plant genotype (Mehan et al. 1986), insect damage to the 
plant (Lynch and Wilson 1991), and drought (Sanders et al. 1993). Periods of drought in 
conjunction with high temperatures can greatly increase the production of AFs since 
damaged crops have increased infection sites that are vulnerable to aggressive wound 
pathogens like A. flavus (Diener et al. 1987). Therefore, populations living in areas with 
these environmental conditions may be at increased risk for AF exposure. In regions 
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between the latitudes 40º N and 40º S, termed the ‘hot zone,’ an estimated 4.5 billion 
people living in developing countries are chronically exposed to AFs (Williams et al. 
2004). Additionally, post-harvest contamination is largely dependent on the adequate 
drying and storage of crops, i.e., relative humidity <85% (Wilson and Abramson 1992). 
The significant economic investment of drying/storage facilities may be not be feasible 
in developing countries. Poor housing conditions for crops that generate areas of local 
condensation (e.g., insect respiration, rodent activity, roof leaks, etc.) provide ideal 
conditions for Aspergillus growth and ensuing AF production (Wilson and Payne 1994). 
In addition to the occurrence of AFs in crops, lactating humans and animals have been 
shown to excrete toxic AF metabolites in milk (aflatoxin M1) after consuming AFB1-
contaminated foods or feeds (Rodericks and Stoloff 1977; Sieber and Blanc 1978; El 
Nezami et al. 1995; Navas et al. 2005; Galvano et al. 2008). Subsequently, AF-
contamination may occur in milk and dairy products (Jones 1995). The young are 
especially at risk due to their reliance on milk as a major source of nutrition.  
1.2 Chemistry of aflatoxins  
 Upon isolation and identification of naturally-occurring AFs, the components 
were subdivided into two groups, B and G, due to their blue and green fluorescence, 
respectively, under ultraviolet light (Hartley et al. 1963). Major members of the AF 
group include four bisfuranocoumarin metabolites B1, B2, G1, and G2 (Figure 1), with 
AFB1 being the most toxic and usually the most predominant (Jones 1977). These main 
congeners: AFB1 (C17H12O6), AFB2 (C17H14O6), AFG1 (C17H12O7), and AFG2 (C17 
H14O7) have molecular weights of 312, 314, 328, and 330, respectively.  
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Aflatoxin B1 Aflatoxin B2
Aflatoxin G1 Aflatoxin G2
 
 
Figure 1. Chemical structures of commonly occurring aflatoxins B1, B2, G1, and G2. The series 
nomenclature denotes characteristic fluorescence emission under UV light: (B) blue or (G) green 
fluorescence. 
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Hydrogenation of AFB1 and AFG1 in the laboratory yields the less carcinogenic 
species AFB2 (C17H14O6), and AFG2 (C17H14O7), which lack the double bond at the C8,9 
position (van der Merwe et al. 1963). When in the presence of inorganic acids, acid-
catalyzed hydration of the C8,9 double bond in AFB1 and AFG1 results in the hemiacetal 
forms, AFB2A and AFG2A, respectively (Ciegler and Peterson 1968; Pohland et al. 1968). 
In various animal species, AFB1 and AFB2 can be hydroxylated at the 9a position to 
yield AFM1 and AFM2, which were originally designated as M due to their discovery in 
milk (Holzapfel et al. 1966). Importantly, all of the AFs are heat stable, surviving 
temperatures up to melting points which range from 237 to 299°C, depending on the 
species (Jones 1977). Therefore, treatment of contaminated foods according to normal 
food processing practices is not sufficient for decontamination. Under the alkaline 
conditions employed during nixtamalization (the preparation of maize in lime solution 
containing calcium), hydrolysis of the lactone ring occurs (Jones 1977). Disruption of 
the compound’s aromaticity renders it undetectable by common analytical methods that 
rely on fluorescence for detection; however, this reaction is reversible in acidic 
conditions (De Iongh et al. 1962). Therefore, reports originally describing the process of 
nixtamalization as a detoxification method should be carefully evaluated since the 
original structure of the toxin is restored in the acidic conditions of the stomach (Price 
and Jorgensen 1985). “Detoxification” by ammoniation has been utilized in California 
and Arizona to decrease parent AF levels in cottonseed intended for dairy cows (Park et 
al. 1988). These methods usually are non-reversible, as they proceed at elevated 
temperatures and pressures, and decarboxylation follows hydrolysis of the lactone ring. 
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The reaction may proceed further to yield AFD1 and a product with a molecular weight 
of 206 (Kiermeier and Ruffer 1974). Due to the potential of detoxification products to 
remain toxic and carcinogenic, the U.S. Food and Drug Administration (FDA) has not 
approved this strategy.             
1.3 Toxicology of aflatoxins   
 Among the AFs, the most prevalent congener, AFB1, is also the most toxic 
(Carnaghan et al. 1963). Wogan et al. (1971) reported median lethal dose (LD50) values 
of 0.73, 1.18, 1.76, and 2.83 mg/kg body weight for AFB1, AFG1, AFB2, AFG2, 
respectively, in a sensitive duckling model. In addition to AFB1, Holzapfel et al. (1966) 
showed that ducklings were extremely sensitive to AFM1, an AFB1 metabolite, with 
LD50 values ranging from 12 to 16 µg/animal. AFB1 is also the most carcinogenic of the 
AFs (Wogan and Newberen 1967); thus, the majority of discussion will focus on the 
toxicology of AFB1. The most common route of exposure is oral via consumption of 
contaminated foods, although occupational exposure to inhaled AFB1 in contaminated 
grain dust may also occur (Sorensen et al. 1981). Animal studies have shown that 
approximately 50% of an orally administered dose of AFB1 is rapidly absorbed from the 
duodenal region of the small intestine (Coulombe and Sharma 1985). AFB1 is 
concentrated in the liver (and to a lesser extent in the kidney) via the portal vein (Wilson 
et al. 1985). Metabolism of AFB1 yields a variety of metabolites, many of which have 
been used as biological markers of exposure (Wild and Turner 2002). Figure 2 illustrates 
AFB1 metabolism by various phase I and phase II enzymes and highlights metabolite 
biomarkers in the blood and urine.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Metabolism of aflatoxin B1 by phase I and phase II enzymes. Phase I enzymes include CYP 3A4 and 1A2. Detoxification of 
epoxide metabolites occurs via microsomal epoxide hydrolases (mEH) and glutathione-S-transferases (GST). *GSTs also conjugate the 
endo-epoxide. Aflatoxin aldehyde reductase (AFAR) acts upon the AF-dialdehyde. Biomarkers are highlighted in blood (white box) and 
urine (gray box). Adapted from Wild and Turner 2002.   8 
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Biotransformation of AFB1, predominantly by human cytochrome P450 (CYP) 
enzymes 3A4 and 1A2 in the liver primarily leads to formation of the AFB1 exo-8,9-
epoxide over the endo-8,9-epoxide (Gallagher et al. 1994; Guengerich et al. 1998). The 
highly unstable exo-epoxide is the ultimate AF carcinogen and forms covalent DNA 
adducts, primarily at the N-7 position of guanine residues (Essigman et al. 1983; 
Gopalakrishnan et al. 1990). This adduct can either undergo cleavage (to be excreted in 
the urine as aflatoxin-N7-guanine) or rearrange to a foramidopyrimidine (FAPY) adduct 
(Croy and Wogan 1981). Ultimately, this adduct triggers a G ? T transversion, which 
may result in genetic alterations that enhance malignant transformation of affected cells 
(Smela et al. 2001). The epoxide ring in the endo isomer (unlike the exo-form) is 
positioned above the plane, in trans to the 5a and 9a protons, hindering its reaction with 
guanine (Raney et al. 1993). Other metabolic pathways, in addition to expoxidation, 
involve the direct hydroxylation of AFB1 by CYP enzymes. Biotransformation by CYP 
3A4 and 1A2 yields AFQ1 and AFM1 metabolites respectively, which are excreted in 
urine (Coulombe 1993). Additionally, O-demethylation of AFB1 produces the urinary 
metabolite AFP1 (Eaton et al. 1994). All three of these hydroxylation products have been 
identified in human urine (Groopman et al. 1985).  
 Detoxification pathways may reduce DNA adduct formation, and an important 
mechanism is through the conjugation of reactive epoxide metabolites to glutathione 
(GSH) by glutathione S-transferase (GST) enzymes (Raney et al. 1992). Upon 
conjugation with GSH, peptidases and acetylases, in order to salvage amino acid 
residues, convert the AF-GSH conjugate to AF-mercapturic acid, which is excreted in 
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urine (Wild and Turner 2002). Hydrolysis of the AFB1-8,9-epoxide by microsomal 
epoxide hydrolases (mEHs) has also been shown; however, there is competition from 
rapid non-enzymatic hydrolysis (Johnson et al. 1997; Guengerich et al. 1998). In either 
case, hydrolysis yields a dihydrodiol that undergoes base-catalyzed ring opening 
rearrangement to form a dialdehyde (Roebuck et al. 1978). This product can be further 
metabolized by AF aldehyde reductase, which reduces the dialdehyde to a dialcohol that 
is then glucuronidated prior to urinary excretion (Hayes et al. 1993). Alternatively, the 
dialdehyde can covalently react with proteins (e.g., albumin) by binding primary amines 
through a Schiff base mechanism (Sabbioni et al. 1987). For instance, the AFB1-lysine 
albumin adduct, a metabolite in peripheral blood, consists of an AF metabolite bound to 
the epsilon amino group in lysine.     
 The carcinogenicity and toxicity of AFB1 in various animal species is largely 
dependent on variances in metabolism. For instance, an almost 100,000-fold difference 
in susceptibility to AF-induced hepatomas is evident in more sensitive trout and rat 
species compared to resistant mice strains. At oral doses as high as 10,000 ppb mice do 
not develop liver cancer; whereas, levels as low as 15 ppb can produce a significant 
increase in liver tumors in rats (Wogan 1973). Differences in GST expression account 
for most of the variation between species. For instance, mice constitutively express an 
alpha-GST isoform (mGST A3-3), which has a high catalytic activity toward the AFB1 
8,9-epoxide; thus, mice conjugate this epoxide up to 50 times faster than rats (Eaton and 
Gallagher 1994). Conversely, rats express a related form of GST with much less activity, 
increasing the lifetime of the ultimate carcinogen. Furthermore, mice readily conjugate 
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the exo-epoxide with GSH while rat and human alpha-GSTs do not readily conjugate the 
exo- or endo-epoxide (Wang et al. 2002). Human μGSTs can conjugate the epoxide; 
however, the endo isomer is preferred (Wang et al. 2000). Therefore, it is suggested that 
humans may be as sensitive to AF-induced hepatomas as rats.  
1.4 Biomarkers of exposure to aflatoxins  
In order for a toxicant to cause an effect, there must first be an exposure. Early 
work estimating human exposure to AFs relied on measurements from contaminated 
foods. However, due to the large variability associated with measuring AF levels in bulk 
food matrices (Whitaker and Park 1994) and reliance on individual dietary recall, the 
application of AF measurement in body fluids via immunochemical methods became a 
more useful method to assess biologically relevant exposure. AF-specific biomarkers 
currently used as measures of individual exposure include AFB1 metabolites and AFB1-
macromolecular adducts (i.e., AFM1 in urine and AFB1-lysine albumin adduct in serum) 
(Groopman et al. 1994, 1996; Wang et al. 2001a). 
1.4.1 Aflatoxin M1 metabolite in urine  
AFM1, a major oxidative metabolite of AFB1, is a reliable biomarker reflective of 
internal dose. The excretion of AFM1 represents recent exposure (i.e., within 24 to 48 
hours) (Groopman et al. 1988; Cheng et al. 1997). Using a monoclonal antibody 
immunoaffinity/high performance liquid chromatography (HPLC) method, Groopman et 
al. (1992) reported that in rats dosed with AFB1, AFM1 accounted for the highest 
percentage of total urinary AF metabolites (34.5), followed by AF-N7-guanine (9.6), 
AFP1 (8.0), AFQ1 (1.8), and AF-dihydrodiol (1.5). Furthermore, AFM1 was found to be 
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an excellent marker linearly associated with AFB1, whereas AFP1 was not found to be 
linear with excretion. AFM1 is also the major AFB1 metabolite in monkeys after i.v. 
dosing (0.3 mg AFB1/kg) and oral administration of [14C]AFB1 (0.4 or 0.015 mg 
AFB1/kg) (Dalezious et al. 1973; Wong and Hsieh 1980). Urinary AFM1 has been 
further characterized and validated in multiple human populations, largely in Asia and 
Africa (Table I). Campbell et al. (1970) originally reported AFM1 as the major 
hydroxylated AFB1 metabolite in urine samples from Filipinos exposed to peanut butter 
containing high levels of AFB1 (~0.5 mg/kg). The predominance of AFM1 in urine was 
confirmed in a large number of samples collected from individuals in Zimbabwe (Nyathi 
et al. 1987). Moreover, Zhu et al. (1987) measured AFM1 in a Chinese population 
frequently exposed to dietary AFs and found a positive correlation (r = 0.65) between 
AFB1 intake and AFM1 excretion over a three day period. Approximately 1.2 to 2.2% of 
AFB1 from the diet was excreted as urinary AFM1, similar to excretion rates reported to 
range from 1 to 4% (Campbell et al. 1970; Nyathi et al. 1987). In addition to measuring 
exposure, AFM1 detection has aided in identifying populations at risk for hepatocellular 
carcinoma (HCC). For instance, the risk of HCC development was shown to be 
significantly increased (by 4.4-fold) in individuals with detectable urinary AFM1 levels 
(Qian et al. 1994). In agreement with these data, Sun et al. (1999) reported a 3.3-fold 
increase in the relative risk of HCC in subjects with detectable AFM1 in a cohort of 
Chinese men chronically infected with hepatitis B virus (HBV). Importantly, findings 
confirmed that AF exposure accounted for a substantial portion of HCC risk in 
individuals with chronic HBV.  
 Table I. Documented ranges of urinary aflatoxin M1 levels in humans. 
 
Country Exposure rate (n)a Reported range  Reference 
Indonesia 38% (68 adults) 0 – >1000 pg/100 ml urine Tsuboi et al. 1985 
Philippines 27% (52 adults) 0 – 968 pg/100 ml urine Tsuboi et al. 1985 
Japan 8% (40 adults) 0 – 66 pg/100 ml urine Tsuboi et al. 1985 
Nigeria 9% (161 adults) 0.89 ng/100 ml urineb Bean et al. 1989 
China (Shanghai) 21% (317 males) 0.17 – 5 .2 ng/ml urine Qian et al. 1994 
China (mainland) 64% (138 males) 0 –108 ng/12h urine Cheng et al. 1997 
Taiwan 66% (32 males) 0 – 17 ng/12h urine Cheng et al. 1997 
Sierra Leone 41% (134 boys)c 0.5 – 374 ng/ml urine Jonsyn-Ellis 2000 
Sierra Leone 44% (110 girls)c 2.3 – 34 ng/ml urine Jonsyn-Ellis 2000 
Sierra Leone 43% (97 boys)d 0.1 – 35 ng/ml urine Jonsyn-Ellis 2000 
Sierra Leone 59% (93 girls)d 0.3 – 124 ng/ml urine Jonsyn-Ellis 2000 
China (Guangxi) 89% (27 adults) 0.9 – 3569.7 ng/24h urine Wang et al. 2001b 
Ghana 91% (91 adults) 0.01 – 17.24 ng/ml urine Jolly et al. 2006 
Egypt 8% (50 children) 5.0 – 6.2 pg/ml urine Polychronaki et al. 2008 
Guinea 64% (50 children) 8.0 – 800 pg/ml urine Polychronaki et al. 2008 
 
aTotal number of people in study; bAverage concentration; cDry season; dRainy season.      
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1.4.2 Aflatoxin B1-lysine albumin adduct in serum   
The AFB1-lysine albumin adduct (or AF-albumin adduct) in serum represents a 
chronic biomarker of biologically effective dose reflecting integrated exposures over two 
to three months due to the 21-day half-life of serum albumin (Sabbioni et al. 1990; 
Wang et al. 1996a). In humans, approximately 2% of ingested AFB1 has been reported to 
be covalently bound to serum albumin (Gan et al.1988), similar to the percentage (1-3%) 
observed in rats dosed with AFB1 (Wild et al. 1996). Like AFM1, positive correlations 
between AFB1 intakes and AF-albumin adduct levels have been observed from several 
regions of the world (Gan et al. 1988; Wild et al. 1990). Furthermore, epidemiological 
studies have shown a relationship between AF-albumin adduct levels and increased HCC 
risk in China (Groopman et al. 1996; Kuang et al. 1996; Wang et al. 2001b), Taiwan 
(Chen et al. 1996; Wang et al. 1996b; Lunn et al. 1997), and Africa (Allen et al. 1992). 
The AF-albumin adduct has also been used as a biological response indicator of 
advanced liver disease in hepatitis C virus patients in Taiwan (Chen et al. 2007) and 
aflatoxicosis in Africa (Azziz-Baumgartner et al. 2005). 
1.5 Consequences of aflatoxin exposure 
Adverse effects due to animal and human AF exposure have resulted in 
significant economic, agricultural, and public health consequences. Human health 
hazards may come in the form of primary or secondary mycotoxicoses, depending on if 
the exposure is from direct consumption of AF-contaminated foods or from animal by-
products, such as AF metabolites in milk (Samson 1992). The dose and duration of 
exposure affect the resulting consequences. Short-term high dose exposure results in 
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acute toxicity, usually in the form of liver cirrhosis, which may cause illness or possibly 
death, whereas chronic sublethal doses can have nutritional and immunological 
consequences (Williams et al. 2004). All doses can have a cumulative effect on cancer 
risk (Roebuck and Maxuitenko 1994).          
1.5.1 Acute toxicity 
 Acute exposure to high levels of AFB1 via the diet causes disease (aflatoxicosis) 
and death in animals and humans. Signs of aflatoxicosis usually include acute hepatic 
necrosis, bile duct proliferation, edema, and lethargy (Cullen and Newberne 1994). The 
sensitivity of various avian species has resulted in notable outbreaks in the poultry 
industry. Historically, the epizootic outbreak in Britain in 1960, which resulted in the 
death of over 100,000 turkeys, emphasized the significant impact of the AF problem 
(Lancaster et al. 1961). Subsequently, a number of studies determined a range of acute 
toxicities for AFB1 in multiple animal species. Susceptible species such as duck (0.36 
mg/kg), rabbit (0.30 mg/kg), and trout (0.81 mg/kg) have much lower LD50 values 
compared to more resistant species such as chickens (18.0 mg/kg) and mice (60 mg/kg) 
(Wogan 1973; Cullen and Newberne 1994). Nonetheless, at high enough concentrations 
AFB1 acts as an acute poison targeting the liver. Massive hepatotoxicity (necrosis and 
hemorrhage) has been identified in the wake of AF outbreaks in the poultry and 
livestock industries (Osweiler and Trampel 1985; Choudary 1986; Van Halderen et al. 
1989). In addition, acute aflatoxicosis in dogs, due to contamination of commercially 
available feeds, has been documented in Texas (Garland and Reagor 2001) and the 
eastern U.S (Stenske et al. 2006). In western India, an epizootic outbreak in dogs 
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preceded human deaths from consumption of heavily molded corn (van Rensburg 1977; 
Shank 1981). Corn containing 6 to 16 mg AF/kg corn was consumed in over 200 
villages, and mortalities occurred in 100 of 400 patients examined. Evidence of clinical 
aflatoxicosis has also been reported in Taiwan and Uganda (Shank 1977, 1981), 
characterized by abdominal pain, vomiting, pulmonary edema, fatty liver infiltration, 
and liver failure (Ngindu et al. 1982). Recently in Kenya, 125 deaths out of 317 cases of 
acute aflatoxicosis from January to July, 2004 was linked to the consumption of meals 
prepared from locally grown and poorly stored maize contaminated with AF levels as 
high as 8,000 ppb (Azziz-Baumgartner et al. 2005; Lewis et al. 2005). This severe 
outbreak reaffirmed the AF problem as a contemporary issue, especially in populations 
living in conditions that may necessitate the consumption of lower quality foodstuffs.   
1.5.2 Growth retardation and impact on vitamins and nutrients   
 A strong relationship between AF exposure and growth impairment has been 
established in many studies with domestic animals. For instance, significantly decreased 
body weight gains and/or reductions in feed conversion efficiencies have been reported 
in Leghorn and broiler chicks (Kubena et al. 1990, 1993b; Huff et al. 1992), turkey 
poults (Kubena et al. 1991), weaning piglets (Lindemann et al. 1993; Marin et al. 2002), 
and growing barrows (Harvey et al. 1989, 1994a) and lambs (Harvey et al. 1991a) 
following exposure to AF-contaminated feed. A similar effect has been shown in 
humans during periods of development. For instance, Gong et al. (2002) demonstrated a 
correlation between decreased z-scores (reflective of growth stunting and underweight) 
and serum AF-albumin adducts in children from Benin and Togo. In utero AF exposure 
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has also been shown to cause growth faltering in infants in The Gambia, signifying the 
vital impact of early life exposure (Turner et al. 2007). In addition to growth 
suppression, the impact of AF on vitamins and micronutrients represents a major public 
health concern, particularly in developing countries where malnutrition or nutritional 
deficiencies are common. Work in animal models and human populations have indicated 
that AFs may affect important fat-soluble vitamins A, D, and E. For example, hepatic 
vitamin A concentrations in broiler chicks were decreased with increasing concentration 
of AFs (0, 500, and 2000 ppb) (Reddy et al. 1989) and significantly reduced following 
dosing with 5000 ppb AFB1 (Pimpukdee et al. 2004). Additionally, Harvey et al. (1994b) 
reported AF exposure in growing barrows resulted in decreased retinol concentrations; 
authors suggested that AF exposure may exacerbate vitamin A deficiencies. Human 
vitamin A modulation as a function of AF exposure has been somewhat inconsistent, 
although the literature is limited. Earlier work showed no relationship between vitamin 
A and AF-albumin adduct levels in Gambian children (Turner et al. 2003); however, 
recent work in an adult Ghanaian population illustrated a strong correlation between 
AF–albumin adduct levels and decreased serum vitamin A (Tang et al. 2009). Further 
work is needed to clarify the role of AFs in reducing vitamin A levels in humans. 
Moreover, the use of AF-albumin adducts as a measure of biological response for 
vitamin A should also be further assessed. Similarly, vitamin D and E levels are affected 
by AF exposure. For example, vitamin D concentrations in broiler chicks were 
significantly reduced following 5-day treatment with 1000 ppb AFs (Glahn et al. 1991). 
An inverse relationship between AF exposure and levels of serum vitamin E has also 
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been shown in growing barrows (Harvey et al. 1994b) and in the same Ghanaian 
population, wherein Tang et al. (2009) showed a correlation between decreased serum 
vitamin E levels in individuals with high AF-albumin adducts. Since vitamins A, D, and 
E play import roles in immune system competence, nutritional interference of AFs may 
impact normal, healthy immune function. Likewise, multiple micronutrients are critical 
to health and immunity. Reports in laboratory and farm animals have shown AF 
exposure interferes with the nutrition of iron (Fe), zinc (Zn), and selenium (Se) (Harvey 
et al. 1988; Dimri et al. 1994; Kalorey et al. 1996; Mocchegiani et al.1998; Hegazy and 
Adachi 2000; Williams et al. 2004). For example, Mocchegiani et al. (1998) documented 
reduced levels of serum Zn (56.0 µg/dL versus 119.2 µg/dL in controls) in piglets 
exposed to AFB1 in utero. Consequently, the cellular immune status of exposed piglets 
was impaired, mainly due to decreased activated thymulin. A similar relationship 
between decreased concentrations of serum Zn and immune system impairment has been 
shown in rats in rats following AF exposure (Doyle et al. 1977; Ikegwuonu et al. 1985). 
Furthermore, Hegazy and Adachi (2000) demonstrated an analogous effect of AFs on Se 
levels and lowered immunity. In humans, AF-albumin levels have been show to be 
inversely correlated with Se concentrations in Chinese men (Chen et al. 2000). Although 
the role of AF exposure on Zn and Fe is not certain in humans, animal data suggest AFs 
may promote deficiencies, particularly in the young. 
1.5.3 Immunosuppression 
 Cell culture work and animal models have demonstrated that AF is an 
immunotoxic agent that primarily suppresses cell-mediated immune responses and 
 19
phagocytic cell function (Bondy and Pestka 2000). While a limited number of studies to 
date have assessed the immunologic affect of AFs in humans, three recent studies 
conducted in West Africa have shed some light on the role of chronic AF exposure on 
the human immune system. For instance, Turner et al. (2003) reported decreased 
secretory immunoglobulin A levels in saliva of Gambian children with detectable AF-
albumin adduct levels. Results from an adult population in Ghana demonstrated a 
marked effect on cellular immune system components and functions in participants with 
high AF-albumin adduct levels (Jiang et al. 2005). Authors hypothesized that changes in 
immunological parameters as a result of AF exposure may increase individual 
susceptibility to infection. This is in concordance with previous animal work showing 
decreased resistance to infectious diseases (Hamilton and Harris 1971; Edds et al. 1973; 
Wyatt et al. 1975; Cysewski et al. 1978; Joens et al. 1981) and induced reactivation of 
chronic infection (Venturini et al 1996; Kubena et al. 2001) following AF exposure. 
Further work by Jolly and co-workers investigated the possible interaction of AF and the 
human immunodeficiency virus (HIV) on immune suppression (Jiang et al. 2008). In this 
report, high AF-albumin adduct levels were associated with lower perforin expression on 
CD8+ cells among all patients regardless of HIV status. However, HIV+ patients with 
high AF-albumin adducts had significantly lower percentages of CD4+ T-regulatory-
cells, naive CD4+ T-cells, and  B-cells compared to HIV+ participants with low AF-
albumin adducts. The immunotoxic effects of AFs in humans should be further explored 
due to the paucity of data and the important role that AFs may play in modulating 
susceptibility to infectious disease.  
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1.5.4 Carcinogenicity   
Perhaps one of the most recognized consequences of chronic AF exposure in 
humans is development of hepatocellular carcinoma (HCC), which is the most common 
form of primary liver cancer and represents the third leading cause of cancer deaths 
worldwide (600,000 deaths annually) (Parkin et al. 2001). Liu and Wu (2010) assessed 
the global burden of HCC attributable to AF exposure and found that of the 550,000-
600,000 new HCC cases worldwide per year, AF may play a causative role in up to 
155,000 cases (28.2% of all global HCC cases). The prevalence of HCC is substantially 
higher in developing versus developed countries. Wild and Hall (2000) estimated that 
80% of all HCC cases occur in developing countries. Historically, studies conducted in 
Asian and African populations demonstrated a positive correlation between HCC 
incidence, largely based on cancer registry data, and high AFB1 intake, calculated from 
analysis of foods consumed. For example, Bulatao-Jayme et al. (1982) showed that the 
relative risk (RR) for liver cancer when consuming a high level of AFs plus a minor 
amount of alcohol was 17.5, as compared with a RR of 3.9 when alcohol consumption 
was heavy and AF intake was low. Based on these types of epidemiological data and a 
large body of work in experimental animals, AFB1 was designated as a known human 
carcinogen (group 1) by the International Agency for Research on Cancer in 1993 
(IARC 1993). A serious confounder in these studies however, was the high rate of 
hepatitis B virus (HBV) in these populations. In areas of high HCC incidence, such as 
sub-Saharan Africa, China, and Southeast Asia, HCC occurrence is closely related to 
HBV infection (Turner et al. 2002). Later studies involving the measurement of AF-
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specific molecular biomarkers (i.e., AFM1 and AF-albumin adduct) and careful 
consideration of HBV status helped elucidate the role of AFs and HBV in HCC 
development. For instance, Ross et al. (1992) demonstrated a strong interaction between 
serological markers of chronic HBV infection, i.e., the HBV surface antigen (HBsAg), 
and urinary AF metabolites in liver cancer risk. In addition, HCC risk was remarkably 
elevated (RR = 59.4) in HBsAg+ individuals who excreted elevated levels of urinary AF 
metabolites when compared with HbsAg+ individuals with non-detectable AF exposure 
(RR = 7.3) (Qian et al. 1994). Subsequent findings, described previously in this section, 
strengthened the conclusion that AF was a causative agent for HCC and co-infection 
with HBV significantly increased HCC risk (Sun et al. 1999). Experiments in HBV-
transgenic mice and woodchucks infected with woodchuck hepatitis virus recapitulated 
the synergistic effect seen in epidemiological studies (Sell et al. 1991; Bannasch et al. 
1995). Although the mechanisms of interaction between AF and HBV in increasing 
hepatocarcinogenicity are not certain, a variety of reasons have been proposed including: 
1) chronic HBV infection may induce activation of AFB1 to the mutagenic epoxide, 
thereby increasing the opportunity for mutation; 2) the generation of reactive oxygen 
species and inflammation resulting from HBV infection may have promoter-like activity, 
increasing the chance of clonal expansion of mutated cells; and 3) HBV may suppresses 
DNA repair mechanisms that may select for carcinogenesis from AFs (reviewed by Kew 
2003). A recent study indicated HBV infection significantly contributes to oxidative 
stress, shown by the oxidative stress biomarker 8-OHdG, in a population chronically 
exposed to AFs, which may contribute to HCC (Liu et al. 2008). 
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Figure 3. Molecular model of aflatoxin B1 intercalated between strands of DNA.  
 
 
 
1.5.5 Biochemical mode of action 
The ability of AFB1 to act as an initiator stems from its bioactivation to a direct-
acting mutagen. Essigmann et al. (1977) first identified the most frequent AF-DNA 
adduct, the 8,9-dihydro-8-(N7-guanyl)-9-hydroxy-AFB1 adduct, modeled above (Figure 
3). Importantly, AFB1 disrupts several genes involved in the progression of cancer. In 
rats dosed with AFB1, a high expression of the activated forms of c-H-ras and c-myc 
proto-oncogenes are observed in hepatic tumors (McMahon et al. 1987). Furthermore, in 
cultured human hepatocytes AFB1 produces a G:C to T:A mutation in the third base of 
codon 249 in the p53 tumor suppressor gene (Aguilar et al. 1993). This mutation has 
been identified in tumors at a high frequency in populations exposed to high levels of 
dietary AFs (Greenblatt et al. 1994); whereas, few such mutations have been observed in 
HCC of patients residing in regions of low AF exposure. This mutational hot-spot has 
been recognized as a ‘molecular fingerprint’ linking initial AFB1 genotoxicity to the 
ultimate progression to HCC. Benzo[a]pyrene (BaP), a model carcinogenic PAH, 
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induces tumor formation using metabolic pathways similar to that observed for AFB1; 
BaP is metabolized to an epoxide (BaP 7,8-diol-9,10-epoxide) which forms DNA 
adducts primarily at nitrogen residues of guanine bases, which is an initial step for the 
malignant transformation of cells (Ross and Nesnow 1999; Miller and Ramos 2001). 
DNA adducts resulting from AFB1 and BaP are illustrated in Figure 4. In addition, BaP- 
induced G:C to T:A transversions in nucleotide residues of the p53 gene have been 
identified in human lung cancers  (Puisieux et al. 1991). Thus, due to similarities of BaP 
and AFB1 in initiating cancer, it was hypothesized that populations frequently exposed to 
dietary AFs may be affected by a concurrent exposure to PAHs.  
 
 
 
 
 
 
 
 
(a)
(c)
dR-DNA
(b)
dR-DNA
 
 
 
 
Figure 4. Similarity of primary aflatoxin B1 and benzo[a]pyrene DNA adducts at nitrogen 
residues of guanine bases. AFB1 and BaP primarily alkylate DNA at the N-7 and N-2 positions 
of guanine (a) to yield the principal adducts shown in (b) and (c), respectively.  
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1.6 Occurrence of polycyclic aromatic hydrocarbons (PAHs) 
 Polycyclic aromatic hydrocarbons (PAHs), also known as polynuclear aromatic 
hydrocarbons, are a class of unavoidable environmental pollutants produced from the 
incomplete combustion of organic material (Samanta et al. 2002). PAHs represent a 
group of several hundreds of chemical compounds composed of fused aromatic rings. 
Representative PAH structures are illustrated in Figure 5. Collectively, PAHs may be 
produced from natural and anthropogenic activities; complex mixtures have been shown 
to occur in the environment (e.g., forest fires, urban air, automobile exhaust, and tobacco 
smoke); in foods (e.g., charbroiled and smoked foods); and in industrial settings (e.g., 
during processing of coal and coal coking and in aluminum and asphalt production 
plants) (Nikolaou et al. 1984). In many developing countries, especially in rural areas, 
indoor wood burning cook stoves or open fires are often employed as the primary means 
of cooking and heating. According to a World Health Organization report assessing the 
global burden of disease (WHO 2008), breathing smoke from traditional cook stoves and 
open fires may have caused as many as 1.96 million premature deaths worldwide in 
2004. Although multiple components make up the list of harmful constituents in smoke 
(e.g., carbon monoxide, particulate matter, volatile organic compounds, etc.), it has been 
well documented that the combustion of wood and other fuels for cooking constitutes a 
significant source of PAHs (Knight and Humphreys 1985; Lioy and Greenberg 1990). 
This suggests that individuals continuously exposed to smoke from these cooking 
methods may be prone to increased PAH exposure. 
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Figure 5. Chemical structures of representative PAH compounds. PAHs vary based on the number (i.e., molecular weights)     
and arrangement (i.e., linear, angular, clustered) of rings. Delocalization of pi-electrons leads to the resonance stabilization.
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1.7 Chemistry of PAHs 
  PAHs are planar, lipophilic, non-polar molecules composed of two or more 
benzene rings that share two or more carbon atoms (Vollhardt 1987). PAH compounds 
and their chemistry vary based on the number (i.e., molecular weights) and arrangement 
of rings (i.e., linear, angular, clustered). Various chemical characteristics of 
representative PAH compounds are illustrated in Table II. Larger molecular weight 
compounds are generally less water soluble and less volatile. Partition coefficients 
between octanol and water (log KOW) are high, which greatly influences their 
bioaccumulation. The well-characterized PAH, benzo[a]pyrene (BaP), consists of five 
fused rings (Figure 5) and has a molecular weight of 252 (Klaunig and Kamendulis 
2007); BaP has a log KOW of 5.97 cm3/g (HSDB 2000). Also shown in Figure 5, pyrene, 
a lower molecular weight PAH (MW = 202), consists of four aromatic rings and has a 
log KOW of 4.88 cm3/g (Lide 1998). Both of these representative PAHs fluoresce at 
characteristic wavelengths and have strong UV absorptions. For instance, the absorption 
maxima (and extinction coefficient) for pyrene in cyclohexane are as follows: 273 nm 
(log ε = 4.77), 306 nm (log ε = 5.07), 320 nm (log ε = 4.51), and 335 nm (log ε = 4.78) 
(Lide 1998). Delocalization of pi-electrons leads to the resonance stabilization of PAH 
compounds. While their aromaticity decreases reactivity, PAHs are not completely 
unreactive. For instance, PAHs can be degraded by photochemical oxidation, 
biodegradation by microorganisms, and metabolism in higher biota (discussed in detail 
in the next section) (Douben 2003).   
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Table II. Chemical characteristics of PAH compounds. 
PAH compound 
No. of 
rings MW 
Sa 
(g/m3 or mg/L) 
Log 
(KOW)b 
Naphthalene 2 128 31 3.37 
Phenanthrene 3 178 1.1 4.57 
Anthracene 3 178 0.045 4.54 
Pyrene 4 202 0.132 5.18 
Benz[a]anthracene 4 228 0.011 5.91 
Chrysene 4 228  5.86 
Benzo[b]fluoranthene 5 252 0.0015 5.80 
Benzo[k]fluoranthene 5 252 0.0008 6.00 
Benzo[e]pyrene 5 252 0.004  
Benzo[a]pyrene 5 252 0.0038 6.04 
Dibenz[a,h]anthracene 5 278 0.0006 6.75 
      
  a Water solubility; bOctanol–water partition coefficient; Table adapted from    
      Douben 2003.  
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1.8 Toxicology of PAHs 
Most exposure to PAHs occurs via the airways, skin and digestive tract. While 
metabolic activation primarily occurs in the liver, the slow absorption through most 
epithelial cells can lead to the induction of CYP enzymes at the site of entry, i.e., 
through activation of the aryl hydrocarbon receptor (AhR) (Swanson 2004). This uneven 
dose distribution may explain the high propensity of PAHs to act as carcinogens at the 
sites of entry (IARC 2010). BaP is one of the most comprehensively studied PAHs; due 
to the vast amount of research conducted, the majority of discussion will focus on the 
toxicology of this specific PAH. BaP is readily absorbed following oral, dermal, and 
inhalation routes of exposure (ATSDR 1990). In rats dosed with 250 mg BaP in the diet, 
60% of the toxin was absorbed across the gastrointestinal tract; furthermore, absorption 
was shown to be enhanced when administered in a lipophilic vehicle (Ekwall et al. 
1951). Following dermal administration in several animal models, the applied dose 
permeated the skin at levels ranging from 0.1% in guinea pigs to 10% in mice (Kao et al. 
1985). After inhalation, BaP was rapidly distributed to several tissues, with highest 
levels found in the liver, esophagus, small intestine, and blood 30 min after exposure 
(Sun et al. 1982; Weyand and Bevan 1986). The metabolism of BaP and pathways 
leading to tumorigenesis have been well-characterized by multiple investigators (Conney 
1982). Initially, BaP is metabolized by CYP enzymes (mainly 1A1, 1A2, and 1B1) to 
several arene oxides, i.e., 1,2-, 2,3-, 4,5-, 7,8-, 9,10-, or 11,12-oxide. These products may 
rearrange to phenols or undergo catalysis by epoxide hydrolases to yield the 
corresponding dihydrodiols. Alternatively, CYPs may directly hydroxylate BaP yielding 
 29
metabolites like the phenol 6-hydroxyBaP, which can be further oxidized to the 1,6-, 
3,6-, or 6,12-quinones. Collectively, these phenol, quinone, and dihydrodiol metabolites 
may be detoxified by phase II enzymes via conjugation to glucuronides, sulfates, or 
glutathione adducts. Alternatively, dihydrodiols may undergo further oxidative 
metabolism to yield highly reactive diol epoxides. This pathway leads to the ultimate 
carcinogenic metabolite, BaP-7,8-diol-9,10-epoxide (BPDE), illustrated in Figure 6 
(Yang et al. 1976; Lowe and Silverman 1994). 
The predominant isomer (+)-anti-BPDE has been shown to possess the highest 
tumor-inducing activity of all the BPDE analogs (Kapitulnik et al. 1978). In mice treated 
with BaP, (-)-syn-BPDE, and (+)-anti-BPDE, 14, 12, and 100% of mice developed 
pulmonary tumors with 0.15, 0.13, and 7.67 tumors/mouse, respectively (Buening et al. 
1978). In vitro studies in a variety of mammalian cells have shown BPDE preferentially 
binds deoxyguanosine at the N-2 position (Meehan et al. 1977; Meehan and Straub 
1979). Unless adducts are efficiently removed by DNA repair, they may trigger G ? T 
transversions similar to the AFB1 adduct (Miller and Ramos 2001). The ‘bay region’ 
theory developed by Lehr and Jerina (1977) indicated that bay region diol-epoxides have 
an increased stability owing to stabilization from angularly fused benzene rings which 
allows sufficient life-time for the direct alkylating agent (i.e., C10) to reach biological 
nucleophiles. Identification of similar regions in other carcinogenic PAHs, like the 
carbonium ion at C1 in the bay region of benz[a]anthracene-3,4-diol-1,2-epoxide, helped 
confirm this theory. BaP excretion is predominantly hepatobiliary followed by 
elimination in the feces (USEPA 2006). Lower molecular weight PAHs have been 
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shown to be excreted in the urine more often than the feces, perhaps owing to their 
increased water solubility (Singh and Weyand 1994).   
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Metabolism of benzo[a]pyrene to ultimate carcinogen. Metabolism by cytochrome 
P450 (CYP) and microsomal epoxide hydrolase (mEH) enzymes yield BaP-7,8-diol-9,10-
epoxide. Adapted from Klaunig and Kamendulis 2007.   
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1.9 Biomarkers of exposure to PAHs  
 PAH exposure levels classically have been estimated through air sampling. Much 
like assessing AF exposure through food measurements, this method does not supply 
information regarding internal dose. Furthermore, air monitoring only estimates 
respiratory intake; therefore, the use of molecular markers in biological fluids is useful 
in quantifying dose and biologically relevant exposure.  
1.9.1 1-hydroxypyrene metabolite in urine   
 The urinary metabolite 1-hydroxypyrene (1-OHP) has been widely accepted as a 
dosimeter of PAH exposure due to the high percentage of pyrene in most PAH mixtures 
(Bouchard and Viau 1999; Hansen et al. 2008). Similar to BaP, pyrene is easily absorbed 
and distributed throughout the body and undergoes phase I metabolism by hepatic CYP 
enzymes. Pyrene is almost exclusively metabolized to 1-OHP and is largely conjugated 
to glucuronic acid or sulfate prior to excretion in human urine (Strickland et al. 1994). 
Since the majority of 1-OHP is excreted as a conjugated product (Law et al. 1994), 
methods of detection require enzymatic hydrolysis to yield the hydroxylated metabolite. 
Jongeneelen et al. (1985, 1987) originally developed a method to measure urinary 1-
OHP and showed excretion was dose-dependent suggesting its use as a biomarker of 
PAH exposure. Since, increased levels of 1-OHP excreted in human urine significantly 
correlate with levels of PAH exposure by inhalation (Ny et al. 1993), oral (Buckley and 
Lioy 1992) and dermal routes (Viau et al. 1995). 1-OHP excretion represents recent 
PAH exposure with half-life values reported to range from 24 to 48 hours, 6 to 35 hours, 
and 16 to 20 hours (Jongeneelen et al. 1990; Buchet et al. 1992). Hence, 1-OHP is 
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regarded as a short-term biomarker of exposure. Moreover, 1-OHP has been extensively 
characterized and validated in many human populations both environmentally and 
occupationally exposed (Jacob and Seidel 2002). Urinary 1-OHP concentrations as high 
as 100 μmol/mol creatinine have been detected in workers exposed to exceedingly high 
levels of PAHs, but values less than 0.1 μmol/mol creatinine are generally observed in 
individuals not occupationally exposed. Background levels of 1-OHP in non-smokers 
and smokers vary from country to country, as illustrated in Table III. Cooking culture 
and behavior influence urinary 1-OHP excretion. For instance Viau et al. (2000) 
measured 1-OHP levels in two populations in Burundi, a central African country. The 
reported range in individuals living in traditional rural houses (0.26 – 15.62 μmol/mol 
creatinine) on average was 30 times higher than levels measured in people living in the 
capital (0.009 – 0.17 μmol/mol creatinine). It was concluded that high doses of PAHs 
were mainly generated by the unventilated burning of wood in traditional homes. Similar 
findings have been shown in a Chinese population, where the widespread use of coal 
burning is common (Zhao et al. 1995). While researchers consider urinary metabolites of 
additional PAHs to be valid, e.g., naphthalene, phenanthrene, and benz(a)anthracene 
(Grimmer et al. 1993, Hansen et al. 1994, Lintelmann et al. 1994, Popp et al. 1997), 1-
OHP remains the most reliable and comprehensively studied biomarker in the urine. 
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Table III. Background 1-hydroxypyrene levels in non-occupationally  
exposed humans from various countries. 
 
1-OHP levels (µmol/mol creatinine)a  Country 
Non-smokers Smokers 
Canada 0.07 (95) 0.13 (45) 
China 0.68b (74) 0.76 b (84) 
Denmark < 0.07 (27) < 0.07 (76) 
Germany  0.04 (90) 0.12 (49) 
Italy  0.08 (19) 0.13 (22) 
Japan 0.06b (7) 0.12b (10) 
Netherlands 0.17 (14) 0.51 (28) 
Sweden  0.03 (48) 0.09 (10) 
Thailand  0.91b (6) 3.03b (7) 
U.S. 0.27 (10) 0.76 (11) 
 Residing in capital Residing in rural area 
Burundi 0.05 c (18) 1.50 c (32)* 
      
  a Data are median levels unless otherwise specified (number of people in study); 
bArithmetic mean concentration; cGeometric mean concentration; *In most studies, 
the 1-OHP level in smokers is significantly greater when compared with non-
smokers (excluding China); however, in Burundi there was no significant 
difference between smokers and non-smokers. Thus, these data are presented 
together un-stratified. Sources: Levin 1995; Viau 2000; Chetiyanokornkul et al. 
2004. 
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1.10 Consequences of PAH exposure 
1.10.1 Non-carcinogenic effects     
Adverse effects due to PAH exposure can be divided into carcinogenic and non-
carcinogenic effects. In terms of non-carcinogenic outcomes, the liver, kidney, and 
vascular system are often the most affected (Klaassen 2007). It has also been 
documented that PAHs cause cellular and humoral immunotoxicity in vitro and in vivo 
(White 1986). The immunological effects of PAHs appear to be biologically relevant, as 
researchers have shown a strong correlation between immunosuppression due to PAHs 
and decreased resistance to infectious agents or transplantable tumor cells in animal 
models (Ward et al. 1984). Moreover, complex effects on human lymphocytes have been 
documented; the high sensitivity of cells suggests human immunity may be adversely 
affected by PAH exposure (Mudzinski 1993; Davila et al. 1996; Burchiel and Luster 
2001). Currently, little is known about the immunotoxic effects of PAHs in humans. In 
an epidemiologic study in coke oven workers in Poland, Szczeklik et al. (1994) noted 
that workers who were highly exposed to PAHs exhibited a marked depression of mean 
serum IgG and IgA and a trended decrease in IgM and increase in IgE. Karakaya et al. 
(2004) showed a statistically significant inhibition in T-lymphocyte proliferative 
responses of asphalt and coke oven workers compared to controls. Significantly higher 
natural killer cell activities were observed solely in the asphalt workers (shown to be 
more highly exposed than controls but less exposed than coke oven workers based on 1-
OHP values). Thus, authors concluded (in agreement with previous literature) that 
chronic exposure to PAHs at different levels may alter immune responses in different 
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ways. Overall, it is apparent that PAH exposure may have important consequences in 
humans in regards to immunity and should continue to be monitored.  
1.10.2 Carcinogenic effects    
Despite the lack of direct experimental evidence of PAH carcinogenicity in 
humans, occupational studies have indicated a strong correlation between PAH exposure 
and the incidence of lung, skin, and bladder cancers (Jacob and Seidel 2002). For 
example, increased cancers of the lung and other tissues (e.g., scrotum, bladder, kidney 
and colon) have been observed in workers employed in coke production and coal 
gasification (Lloyd 1971; Doll et al. 1972; Mazumbar et al. 1975; Redmond et al. 1976, 
1981; Chau et al. 1993; Costantino et al. 1995). Furthermore, elevated rates of skin 
cancer have been observed in workers chronically exposed to coal tar, coal tar pitch, or 
creosote (wood preserving materials shown to be predominantly composed of PAHs) 
(Malaiyandi et al. 1982; Karlehagen et al. 1992). Thus, complex mixtures of PAHs have 
been identified as carcinogenic to humans (IARC 2010). PAHs containing more than 
three aromatic rings account for 70–90% of the total carcinogenic effect (IARC 1973, 
1983; WHO 1998), and the USEPA (2006) has classified the following seven PAHs as 
probable human carcinogens: benz[a]anthracene, benzo[a]pyrene, benzo[b]- and 
benzo[k]-fluoranthene, dibenz[a,h]anthracene, indeno[1,2,3-cd]pyrene, and chrysene. 
Environmental PAH exposure, which is largely variable, has been harder to link to 
carcinogenic effects, although causal relationships do exist. A major source of 
environmental exposure is from environmental tobacco smoke (ETS). ETS exposure has 
been correlated with an increased risk of lung cancer (Pershagen 1994), and PAHs are 
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likely to be among the carcinogenic agents responsible. In addition, urban air pollution, 
which is a complex mixture of chemicals including PAHs, appears to be associated with 
an increased risk of lung cancer in humans (reviewed by Pershagen and Simonato1993; 
Hemminki and Pershagen 1994). 
To date, little research has investigated the carcinogenic effect of environmental 
PAHs on human HCC. Chen et al. (2002) showed higher levels of PAH-albumin adducts 
in non-tumor tissues of HCC patients in Taiwan compared to controls. In a long-term 
follow up study in the same area, an increased risk of HCC was associated with higher 
levels of PAH-albumin adducts; HCC risk was highest among participants who were 
also exposed to high levels of AFs, based on the AF-albumin adduct, and chronically 
infected with HBV (Wu et al. 2007). Thus, enhanced hepatocarcinogenicity of AFs or 
HBV due to PAH exposure may be probable. The molecular pathogenesis of HCC 
involves multiple genetic aberrations in the control of hepatocyte proliferation, 
differentiation, and death (Mínguez et al. 2009). Effects on hepatocyte proliferation have 
been observed in animals following PAH exposure. For instance, cell proliferation 
(determined by organ weight and mitotic index) was investigated in rats dosed with 
fluorene (Danz et al. 1991). Results demonstrated that liver weight increased in a dose-
dependent manner to 20% over control values, and the mitotic index of the hepatocytes 
was increased by 6-fold after 48 hours. Additionally, Ah-responsive strains of mice 
(C57BL/6, C3H/HeN, BALB/cAnN) orally administered BaP (120 mg/kg/day) in their 
diet for 6-months exhibited a 13% increase in relative liver weights (Robinson et al. 
1975). Thus, a possible mechanism may be through the effect of PAHs on hepatic 
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growth. In addition, liver injury resulting from hepatitis infection may lead to enhanced 
cell proliferation; as a result, mutated cells from carcinogenic PAH insult may undergo 
clonal expansion. While prevention of HBV infection is promising, as vaccination is 
becoming more widespread, this is still a long-term strategy in many low and middle 
income countries where HBV continues to persist (Hall and Wild 2003). In addition, no 
vaccine is currently available for other hepatitis viruses, namely hepatitis C virus (HCV), 
which accounts for many HCC cases worldwide. Therefore, a reduction in PAH and AF 
exposures may aid in reducing the overall burden of HCC, particularly in populations 
with high rates of hepatitis. Due to the severe negative health effects associated with 
these foodborne/environmental exposures (both carcinogenic and non-carcinogenic), 
innovative detoxification strategies have been developed. One such approach that has 
shown promise for the management of AFs as a sustainable public health intervention is 
clay-based enterosorption. Although no interventions have been reported for PAHs using 
enterosorbent strategies, some reports have described interference with PAH 
gastrointestinal absorption using organic materials (discussed below).   
1.11 Detoxification of aflatoxins by clay-based enterosorption  
The inclusion of various binding agents or “detoxifying clays” in the diet has 
been given considerable attention as a strategy to reduce foodborne exposures to 
mycotoxins. For centuries, humans and animals have been reported to eat clay minerals, 
a process known as geophagy (Carretero 2002). In the Amazon of Southeastern Peru, 
macaws have been reported to flock to riverbanks daily to eat clay from distinct strata. 
The birds’ diet largely consists of seeds that contain toxic alkaloids, which have been 
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proposed to be sorbed by the clay (Munn 1994). The consumption of edible clays by 
people in various regions of the world (e.g., China and many South American and 
African countries) is common and considered culturally acceptable (Johns and Duquette 
1991; Diamond 1999). Even in the U.S., people have reportedly ingested clay for a 
variety of reason, including as a means of reducing symptoms of morning sickness 
during pregnancy (Ferguson and Keaton 1950; Loggi et al. 1992). Thus, the addition of 
non-nutritive clay minerals in the diet (given the safety and efficacy) represents a 
practical approach for reducing AF exposure from contaminated foods. Using multiple 
animal models, Phillips et al. (1995, 2002, 2008) has shown that NovaSil (NS) clay, a 
dioctahedral smectite, can prevent the adverse effects of exposure to dietary AFs by 
reducing toxin uptake and bioavailability. 
1.11.1 Smectite clay mineral structure and chemistry  
The ability of AFs to be adsorbed onto clay surfaces is largely dependent on the 
clay mineral structure. Multiple studies have confirmed that the active ingredient for AF 
binding is smectite clay (Phillips et al. 2002; Kannewischer et al. 2006; Marroquin-
Cardona et al. 2009). The clay fraction of soils is dominated by phyllosilicate minerals 
(including smectite clays) with high surface areas and unique cation exchange properties 
(Schulze 1989). In general, phyllosilicates are composed of layer-lattice silicates with 
repeating layers of tetrahedral and octahedral sheets. In the tetrahedral layer, each SiO4 
tetrahedron (Si4+ held in tetrahedral coordination by four O2- ions) shares three O2- ions 
with three adjacent tetrahedra. The distinct layers of phyllosilicates form due to the 
ability of the apical oxygens (unbound O2- ions) to replace hydroxyl (OH-) groups in the 
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octahedral layer and coordinate metal cations. Depending on if divalent (e.g., Mg2+) or 
trivalent (e.g., Al3+) cations are held in corrdination with oxygens and OH- groups in the 
octahedral layer, the arrangement is termed trioctahedral or dioctahedral, respectively 
(since to balance the charge divalent cations must fill three of three available sites and 
trivalent cations need only fill two of three spaces). Condensation of layers may be in a 
1:1 proportion (i.e., kaolinites) or 2:1 proportion (i.e., smectites, vermiculites, mica) 
where the octahedral layer is sandwiched between two tetrahedral layers (Schulze 1989).  
Many phyllosilicates possess unique cation exchange properties due to 
isomorphous substitutions of cations that results in a permanent net negative charge, i.e., 
Al3+ for Si4+ in the tetrahedral layer or Mg2+ for Al3+ or Fe3+ in the octahedral layer 
(McBride 1989). To balance the resulting charge, cations such as Na+ and Ca2+ are 
attracted to the negative region between the layers (the interlayer). The amount of charge 
is dependent on the amount of isomorphous substitution. For instance, smectites have an 
intermediate charge per formula unit of 0.25 to 0.6, affording smectites characteristic 
swelling properties as interlayer cations are subject to layers of hydration (Bohn et al. 
1979). Montmorillonites are a subclass of smectites that contain isomorphous 
substitution in the octahedral sheets. These clays are naturally abundant and have surface 
areas as high as 800 m2/g making them ideal sorbent materials (Borchardt 1989). NS 
clay is a naturally occurring calcium montmorillonite (dioctahedral smectite), modeled 
in Figure 7. Given its GRAS status (generally recognized as safe) NS has commonly 
been used as an anti-caking agent in animal feeds at levels up to 2.0%. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Molecular model of smectite clay structure. This schematic representation shows hydrated calcium (green) as the predominant 
interlayer cation. Molecular modeling studies have illustrated AFB1 is predominantly bound within the interlamellar region of NS clay, a 
dioctahedral smectite. Key: Si4+ (yellow) compose the tetrahedral layer and Al3+ (blue) ions are coordinated in the octahedral layer. O (red) 
and H (white). 
40 
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Figure 8. Langmuir mathematical equation. This equation describes the amount of ligand 
adsorbed (q), the maximum amount of ligand that could be sorbed by a given weight of sorbent 
under optimum experimental conditions (Qmax), the equilibrium concentration of ligand in 
solution (Cw), and the equilibrium constant (Kd) which depicts sorbent affinity.  
 
 
 
 
1.11.2 NovaSil clay research  
Several in vitro studies have assessed the sorption of AF onto the surface of NS 
clay (previously referred to as HSCAS in the literature) (Grant and Phillips 1998; 
Phillips 1999). Isothermal data fit to the Langmuir equation (Figure 8) demonstrate high 
capacity (Qmax) and high affinity (Kd) characteristics for AFB1 sorption onto NS. The 
calculated enthalpy of sorption (ΔHads) reported at –40 to –50 kJ/mol indicates multiple 
sites on the surface of NS clay may act to chemisorb AFB1. Additionally, molecular 
modeling studies and experiments comparing isothermal data from heat-collapsed NS 
illustrate AFB1 is predominantly bound within the interlamellar region of NS clay, most 
likely in a planar orientation. Figure 9 illustrates the notably lower capacity (94% less) 
for heat collapsed NS (0.0267 mol/kg) versus unmodified NS (0.456 mol/kg). 
Importantly, isothermal analyses have shown that NS tightly and preferentially sorbs 
AFB1 and similar analogs that contain an intact β-dicarbonyl system. The partially 
positive (i.e., electron poor) carbons comprising the dicarbonyl system (C1 and C11) 
have been shown to be essential for sorption. 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Isothermal plots of untreated versus collapsed NS clay. Isothermal sorption plots demonstrate the notably lower capacity (Qmax) 
for collapsed NS (col-NSP, gray) compared to untreated NS (NSP, black). Computer-generated isotherm data were fitted using the 
Langmuir model. The solid lines show the curve fits whereas the experimental data are represented by the average data points ± SEM. 
Adapted from Afriyie-Gyawu 2004.  42 
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A large volume of scientific literature has indicated that dietary inclusion of NS 
clay (or HSCAS) is safe and effective for reducing AF exposure in multiple animal 
models (Table IV). In chicks dosed with [14C]AFB1, NS at 0.1 and 0.5% markedly 
diminished radioactivity in the blood and hepatic tissues of treatment groups compared 
to controls suggesting NS may reduce AF adsorption and distribution to target organs, 
thereby decreasing AF bioavailability in vivo (Davidson et al. 1987). Furthermore, NS 
addition to the diet has been shown to prevent the adverse effects of AFs in a variety of 
species including chickens (Phillips et al. 1988; Kubena et al. 1990, 1993b, Pimpukdee 
et al. 2004), turkey poults (Kubena et al. 1991), pigs (Harvey et al.1989, 1994a; 
Lindemann et al. 1993), lambs (Harvey et al.1991a), mink (Bonna et al. 1991), and 
pregnant rodents (Mayura et al. 1998). Notably, NS (at 0.5%) protected poultry against 
7.5 ppm AF in the diet, signifying it may be used to reduce exceptionally high levels of 
AFs, such as those observed in outbreak situations (Phillips et al. 1988). Dietary NS 
inclusion has also reduced AFM1 residues in milk of dairy cows and goats and urine of 
rats, turkeys, and dogs indicating its ability to reduce AF biomarkers exposure (Harvey 
et al. 1991b; Smith et al. 1994; Sarr et al. 1995; Edrington et al. 1996; Mayura et al. 
1998; Bingham et al. 2004). While NS intervention has clearly demonstrated efficacy for 
AFs, the same effectiveness has not been shown for other mycotoxins (e.g., zearalenone, 
deoxynivalenol, T-2 toxin, ochratoxin A, cyclopiazonic acid, and ergotamine). The 
adverse effects of these toxins were not prevented upon NS inclusion in the diet 
signifying the preferential binging of AFs by NS (Bursian et al. 1992; Chestnut et al. 
1992; Huff et al. 1992; Kubena et al. 1993a; Dwyer et al. 1997).  
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Table IV. Comparison of in vivo studies with NS clay 
 
Species AF in 
feed 
% NS in feed 
(duration) 
Toxicity 
from NS 
Major effects of NS clay reported 
in study 
Reference 
Chicken Yes 0.5 (28 d) None Growth inhibition diminished Phillips et al. 1988 
Chicken Yes 0.1/0.5 (24 h) None Reduced bioavailability of AF to the liver  Davidson et al. 
1987 
Chicken Yes 0 – 1.0 (21 d) None Feed conversions improved; growth 
inhibition diminished 
Doerr 1989 
Chicken Yes 1.0 (21 d) None Growth inhibition completely prevented Ledoux et al. 1999 
Chicken Yes 0.5 (21 d) None Decreased growth inhibitory effects Huff et al. 1992 
Chicken Yes 0.5 (21 d) None Diminished growth inhibition Kubena et al. 1990 
Chicken No 0.5/1.0 (14 d) None NS did not impair phytate or inorganic 
phosphorous utilization 
Chung and Baker 
1990 
Chicken No 0.5/1.0 (14 d) None NS did not impair utilization of riboflavin, 
vitamin A, or Mn 
Chung et al. 1990  
Chicken Yes 0.125 – 0.5 (21 d) None Protected against vitamin A depletion in 
the livers of chicks exposed to aflatoxins 
Pimpukdee et al. 
2004 
Chicken No 0.5 (19 d) None Did not affect growth performance or tibial 
mineral concentrations of chicks 
Southern et al. 
1994 
Turkey Yes 0.5 (21 d) None Decreased mortality Kubena et al. 1991 
Turkey Yes 0.5 (21 d) None Decreased urinary excretion of AFM1 Edrington et al. 
1996 
Pig Yes 0.5 (42 d) None Diminished growth inhibition Lindemann et al. 
1993 
Pig Yes 0.5/2.0 (28 d) None Diminished growth inhibition, hepatic 
lesions and immunosuppression 
Harvey et al. 1988 
Pig Yes 0.5/2.0 (28 d) None Decreased growth inhibition; prevention of 
serum effects and hepatic lesions 
Harvey et al. 1989 
Pig Yes 0.5 (35 d) None Growth inhibitory effects reduced Schell et al. 1993 
Dog Yes 0.5 (48 h) None Significantly reduced the bioavailability of 
aflatoxins and urinary AFM1  
Bingham et al. 
2004 
Lamb Yes 2.0 (42 d) None Diminished growth inhibition and 
immunosuppression 
Harvey et al. 
1991a 
Cow Yes 0.5/1.0 (28 d) None Reduction of AFM1 in milk Harvey et al. 
1991b 
Goat Yes 1.0/2.0/4.0 (12 d) None Reduction of AFM1 in milk Smith et al. 1994 
Rat Yes 0.5 (48 h) None Decreased urinary excretion of AF 
metabolites (M1 and P1) 
Sarr et al. 1995 
Rat Yes 0.5 (21 d) None Significant prevention of maternal and 
developmental toxicity 
Mayura et al. 1998 
Rat No 0.25 – 2.0 (6 mo) None No adverse effects including vitamin 
utilization 
Afriyie-Gyawu et 
al. 2005a 
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While the potential affect of NS on bioavailability of PAHs from the 
gastrointestinal tract has not been investigated, it is not likely that NS would be effective 
based on the previous specificity data and the importance of a charged/partially charged 
moiety for NS adsorption (Phillips 1999, Phillips et al. 1995). Alternatively, clays 
exchanged with various cationic surfactants (organoclays) have been shown to be 
effective sorbents for a variety of PAHs in solution (Smith and Jaffe 1994; Xu et al. 
1997). In vitro findings have indicated that organoclay-composites, specifically 
cetylpyridinium exchanged low-pH montmorillonite clay (CP-LPHM), have a high 
capacity for contaminants found in aqueous wood preserving waste (Ake et al. 2003; 
Wiles et al. 2005). Authors proposed that inclusion of CP-LPHM may be an effective 
strategy for groundwater remediation of high concentrations of PAHs, in particular high 
molecular weight and carcinogenic PAHs. Regrettably, the use of organoclays as 
enterosorbents in the diet is not a prudent strategy since these clays exhibited toxicities 
in initial safety studies in animals (Afriyie-Gyawu et al. 2005b).  
In all of the short-term animal studies with NS clay, no observable adverse 
effects were noted following dietary ingestion (Phillips 1999; Phillips et al. 2002). These 
data suggest long-term use is feasible. Hence, Afriyie-Gyawu et al. (2005a) investigated 
the safety of dietary NS inclusion (up to 2%, w/w) in a chronic study in Sprague-Dawley 
rats. After 6.5-months of treatment, there were no dose-dependent or NS-related adverse 
effects on body weight gains, relative organ weights, histological appearance of major 
organs, or hematological and serum biochemistry parameters. As a result of the 
extensive safety data in animal models, it was hypothesized that NS may be safe and 
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beneficial for humans, particularly in populations at high risk for aflatoxicosis. As 
precursor to a human intervention study, a short-term adverse events trial was conducted 
to evaluate the safety and tolerance of NS capsules in healthy human volunteers (n = 50). 
After two weeks of capsule ingestion,  NS (up to 3.0 g/day) was considered safe for 
long-term intervention studies based on physical examination results, biochemistry, 
hematology, and selected micronutrient parameters which did not differ significantly 
compared to baseline levels at the start of the study (Wang et al. 2005). This study 
provided the basis to conduct the first Phase IIa human intervention trial in the Ashanti 
Region of Ghana, of which the main objectives of this research focus.  
1.12 Research objectives 
Since AF contamination of foods is a long-standing, seemingly inextricable 
problem (CAST 1989; Phillips 1999; Phillips et al. 2002), there is a need for safe and 
effective interventions. A lack of untainted foods represents a serious burden in many 
parts of the world; thus, detoxification strategies should be economically viable and 
culturally acceptable in addition to being safe and effective. Inclusion of NS clay in the 
diet meets the above mentioned requisites and represents a practical, effective approach 
to diminish or block exposure to AFs. Still, long-term use in humans requires careful 
observation of safety parameters and interactions with micronutrients. In addition to 
dietary AF exposure, populations may be at increased risk for cancer and disease due to 
supplementary factors such as PAH exposure. Measurement of molecular dosimeter 
biomarkers offers a way to identify populations that are vulnerable to both AF and PAH 
exposures. Consequently, biomonitoring is important for comparing public health risks 
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from foodborne/environmental exposures across populations, especially in developing 
countries and underserved rural or metropolitan communities where the incidence and 
impact of these exposures are elevated. Studies in this dissertation focus on the 
measurement of biomarkers with the following specific objectives:  
 
1) to evaluate the effectiveness of NovaSil (NS) clay to act as an enterosorbent 
for AFs in humans after 3-mo intervention in a population chronically 
exposed to AFs (i.e., the Ashanti Region of Ghana) by measuring urinary 
AFM1 as an indicator of intervention efficacy;  
2) to investigate interactions of NS with important nutrient minerals by 
measuring serum mineral concentrations before and after NS intervention;  
3) to determine PAH exposure in this population shown to be at risk for 
aflatoxicosis by measuring 1-OHP in urine samples and to verify if a 
relationship between AF and PAH exposures exists; of additional interest is 
to investigate the possible consequences of enterosorbent intervention on 
PAH exposure;  
4) to assess AF and PAH exposure in a vulnerable U.S. population with an 
elevated incidence of HCC; to investigate dietary factors that may contribute 
to increased AF exposure; and to evaluate other factors that may contribute to 
this increased HCC incidence, namely the prevalence of hepatitis infection in 
the population.   
 
 48
II. NOVASIL CLAY INTERVENTION IN A GHANAIAN POPULATION AT 
HIGH RISK FOR AFLATOXICOSIS: REDUCTION OF URINARY 
AFLATOXIN M1 BIOMARKER* 
 
2.1 Introduction  
Given the safety and efficacy of NovaSil (NS) clay, as demonstrated in a variety 
of animal models, it was hypothesized that NS-based intervention may benefit humans 
who are frequently exposed to high levels of AFs and at risk for aflatoxicosis. The 
previously conducted Phase I adverse events trial (Wang et al. 2005) provided the basis 
for our first objective, to evaluate the efficacy of NS clay for reducing biomarkers of AF 
exposure (i.e., AFM1) in a clinical intervention trial. In order to achieve this aim, we 
conducted a 3-month double-blind, placebo-controlled Phase IIa intervention trial in the 
Ashanti Region of Ghana, a West African country. Previous reports have indicated that 
AF contamination of foods, particularly maize and groundnuts constitutes a major food 
safety problem in Ghana. For instance, Jesperson et al. (1994) reported that in 15 out of 
16 market samples of kenkey, a traditional food made from fermented maize dough, the 
total AF levels ranged from 6.15 to 196.10 ppb, with a mean value of 50.88 ppb. An 
additional study indicated high levels of AF contamination in groundnut samples from 
local markets in ten regions, with levels ranging from 5.7 to 22,168 ppb (Awuah and 
                                                 
* Parts of the data reported in this chapter are reprinted with permission from “NovaSil clay intervention in 
Ghanaians at high risk for aflatoxicosis: I. Study design and clinical outcomes” by Afriyie-Gyawu E, 
Ankrah NA, Huebner HJ, Ofosuhene M, Kumi J, et al. 2008a. Food Addit Contam 25:76–87, Copyright 
[2008] by Taylor & Francis; “NovaSil clay intervention in Ghanaians at high risk for aflatoxicosis: II. 
Reduction in biomarkers of aflatoxin exposure in blood and urine” by Wang P, Afriyie-Gyawu E, Tang Y, 
Johnson NM, Xu L, et al. 2008. Food Addit Contam 25:622–634, Copyright [2008] by Taylor & Francis.    
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Kpodo et al. 1996). These levels reported are well above action levels for AFs permitted 
in foods for human consumption, which range from 0.5 – 50 ppb depending on the 
country and food matrix (Adams and Motarjemi 1999). The Ejura-Sekyedumase district 
(ESD), one of the 21 districts in the Ashanti Region, was chosen as the study site based 
on previously reported biomarker levels confirming this population was at high risk for 
AF exposure and disease. In this report, Jolly et al. (2006) detected the AFB1-lysine 
albumin adduct in 100% of 140 blood samples and the AFM1 metabolite in 91.2% of 91 
urine samples. Moreover, high AFM1 levels were measured in the urine of most study 
participants (mean ± SD = 1,800.14 ± 2602.01 pg AFM1/mg creatinine). Hence, the ESD 
comprised a well-defined study population known to be at high risk for aflatoxicosis.  
2.2 Materials and methods 
2.2.1 Chemicals and reagents   
Authentic AFM1 reference standards were purchased from Sigma Chemical Co. 
(St. Louis, MO). UV-visible spectrophotometry (350 nm; ε=18,815 M–1cm–1) was used 
to verify the concentration of AFM1 stock solutions. All of the experiments were done 
using filtered and deionized water (18.2 MΩ.cm) (Millipore, Milford, MA) and HPLC-
grade solvents. Preparative monoclonal antibody columns (AflaTest® WB) were 
purchased from Vicam (Watertown, MA). All other chemicals and reagents used were 
obtained commercially at the highest purity available.  
2.2.2 Procurement of test article (NovaSil clay) 
NS clay was obtained from Engelhard Chemical Corporation (Iselin, NJ). Prior to 
the intervention study, NS was evaluated for potential environmental contaminants 
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including polychlorinated dibenzo-p-dioxins/furans (PCDDs/PCDFs) and heavy metals 
to ensure their levels met U.S. and international standards. Evaluation of NS for the U.S. 
Environmental Protection Agency (USEPA) priority dioxins/furans was performed by 
Columbia Analytical Services (CAS), Inc. (Houston, TX). Standardized procedures were 
used for sample preparation, cleanup, and analysis with high resolution capillary column 
gas chromatography/high resolution mass spectrometry (USEPA Method 1613B). NS 
was further analyzed for heavy metals, according to EPA, by CAS, Inc. (Kelso, WA). 
Metal analysis procedures followed standard USEPA protocols (e.g. 200.8, 6010B and 
7471A). Following analyses, NS was determined to contain acceptable levels of 
contaminants and was sent to College Pharmacy (Colorado Springs, CO) for 
encapsulation under sterile conditions in a setting with good manufacturing practices.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Capsules used in clinical intervention trial in Ghana. Treatment doses were 0, 1.5, or 
3.0 g NS/day. All capsules were the same size, shape and color to ensure participants were 
blinded to respective dose groups.   
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Capsules, shown in Figure 10, were formulated to contain 500 mg NS (high 
dose), 250 mg NS:250 mg placebo (low dose), or only placebo (microcrystalline 
cellulose) based on previous dosimetry protocols (Wang et al. 2005). Isothermal 
adsorption analysis confirmed the lack of binding capacity for AFs by the placebo 
(Figure 11). All capsules were sterilized by electron beam irradiation at the National 
Center for Electron Beam Food Research, Texas A&M University (TAMU). A target 
dose range of 8.2 – 9.4 KGy was applied and followed protocols similar to those used 
for sterilizing foods in the U.S.  
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Figure 11. Isothermal plots of NS clay versus placebo (cellulose). Computer-generated isotherm 
data were fitted using the Langmuir model. Solid lines indicate the best curve fits whereas the 
experimental data are represented by the average data points. Plots demonstrate the notably 
lower capacities for the PL (red) and NS:PL mixture (blue) compared to NS (black). These data 
confirmed the lack of binding capacity for AFB1 by the PL. 
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2.2.3 Overall study design and procedures 
The overall study design followed the guidelines for a randomized, double-blind, 
placebo controlled Phase II clinical trial. The study protocol was approved by the 
Institutional Review Board (IRB) at TAMU and Noguchi Memorial Institute for Medical 
Research (NMIMR) IRB for Ethical Clearance at The University of Ghana. Screening of 
volunteers was initiated in September, 2005. The trial started in December 2005 and was 
completed in April, 2006 (including 1-month post trial follow-up). Figure 12 shows the 
overall study design and sample collection procedure. Briefly, 180 participants were 
recruited from a total of 507 screened volunteers. This sample size was chosen based on 
the standard 100 to 300 subjects required by the U.S. NIH Guidelines for Phase II 
clinical studies. Individuals (males and females) who qualified as study participants met 
the following criteria: signed informed consent, age 18-58 yr, healthy status based on 
physical examination, normal ranges of hematological parameters and liver and renal 
function indicators, no history of chronic disease(s), no use of prescribed medications for 
chronic or acute illness, non-pregnant and/or non-breastfeeding females, intake of corn 
and/or groundnut-based foods at least 4 times a week, and serum AF-albumin adduct 
levels > 0.5 pmol AFB1/mg albumin. Participants were randomly assigned to one of 
three groups: high dose (HD), low dose (LD), or placebo (PL) and took two capsules 
containing either 500 mg NS, 250 mg NS, or placebo three times per day (before meals 
and with at least 100 ml of water). In total, the HD and LD groups received 3.0 g NS/day 
and 1.5 g NS/day, respectively.  
 
  507 Volunteers
 
Month 4
Month 3
Month 1
60 60 60
Blood, urine
Blood, urine
Blood, urine
PL LD HD
Screening AF-albumin adduct     
> 0.5 pmol/mg albumin
 
 
180 Enrolled Blood, urine 
 (baseline)
 
 
 
 
 
 
 
 
 
 
Figure 12. Overall study design and sample collection procedure for the Phase IIa clinical intervention trial in Ghana. 53 
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The high dose, 0.25% NS (w/w), represented the minimal effective dose (MED) 
shown to significantly reduce the effects of AFs in animals (Pimpukdee et al. 2004). 
Furthermore, no adverse effects were demonstrated in experimental animals dosed at 
levels approximately eight times higher (Afriyie-Gyawu et al. 2005a). To ensure 
maximum compliance to the defined treatment regimens and participant well-being, 
trained study monitors delivered the capsules daily, witnessed ingestions, and recorded 
any symptoms that subjects might have experienced. Physical examinations were 
performed monthly to evaluate the general health status of study subjects. Blood and 
urine samples were collected from each study participant at the beginning of the study 
(baseline), at 1- and 3-months of intervention, and 1-month following completion of the 
trial. Aliquots of the first urines collected were stored in polypropylene tubes and 
shipped to TAMU where they were kept frozen at -80°C until urinary analysis. Serum, 
plasma and blood cells were immediately separated and transported to Texas Tech 
University (Lubbock, TX) where they were stored at -80°C until biomarker analysis. 
2.2.4 Urinary aflatoxin M1 analysis  
 Urinary AFM1 levels were analyzed with immunoaffinity column purification 
followed by HPLC with fluorescence detection developed by Groopman et al. (1992) 
with modifications of Sarr et al. (1995) and Wang et al. (1999). Urine samples were 
thawed and centrifuged at 500 × g for 5 min to remove particulate matter. Each sample 
(5.0 ml urine) was subsequently adjusted to an acidic pH with 0.5 ml of 1.0 M 
ammonium formate (pH 4.5). The volume was increased to 10 ml with deionized water, 
and samples were loaded on immunoaffinity columns at a flow rate of approximately 0.3 
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ml/min. After washing, the purified AF fraction was eluted with 80% methanol and dried 
under N2 for analysis using a Waters HPLC system (Waters Corporation, Milford, MA). 
Excitation and emission parameters were set at 365 and 425 nm, respectively. A 250 mm 
x 4.6 mm LiCrospher RP-18 endcapped column with a pore size of 100 Å and a particle 
size of 5 μm (Alltech Associates, Deerfield, IL) was used to resolve AF metabolites. The 
mobile phase consisted of 22% ethanol in water buffered with 20 mM ammonium 
formate (pH 3.0). Chromatographic separation was achieved by isocratic elution of the 
mobile phase for 25 min. Samples (100 μl) were injected on the column at an elution 
rate of 1.0 ml/min. The limit of detection (LOD) for this method was 0.5 pg AFM1/ml of 
urine. AFM1 quantification was based on peak area and retention time compared to 
external standards injected daily. Urinary creatinine (mg/dL) was measured at St. 
Joseph’s Regional Health Laboratory in order to adjust for variation in urine dilution. 
 Authentic AFM1 standard (5 µg) was initially dissolved in acetonitrile (2 cc) as a 
stock solution and was then diluted in 80% methanol/20mM ammonium formate (pH 
3.0) (1:1, v/v) to serve as an external standard. The machine was calibrated daily by 
injecting multiple aliquots of AFM1 standard solution. Calibration curves were linear 
over the tested range of 1 – 5 ng (r2 = 0.9998) for the instrument. The AFM1 peak was 
detected at a retention time averaging 15.4 min (Figure 13), and its identity (from 
standard injections and representative participant samples) was verified with mass 
spectrometry (Texas Veterinary Medical Diagnostic Laboratory, College Station, TX) 
(Figure 14).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Representative HPLC chromatograph showing urinary aflatoxin M1 metabolite peaks. A representative sample 
collected from a study participant at baseline is shown in red. Peak areas were used for quantification of AFM1 in participant 
samples as compared to external AFM1 standards injected daily, for instance, a 50 ng/ml AFM1 standard peak is shown in black.  
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Figure 14. Representative chromatograms confirming AFM1 structure. Following HPLC 
separation, the identity of AFM1 was verified in a 10 ppb reference standard in acetonitrile (a), a 
10 ppb reference standard in blank urine (b), and a representative urine sample using mass 
spectrometry.   
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2.2.5 Statistical analysis 
Median, mean, standard deviation (SD) and range were calculated for 
concentrations of urinary AFM1 standardized to urinary creatinine. AFM1 levels below 
the LOD were assigned a value of half the LOD for statistical analysis. All data 
generated were analyzed with SPSS software version 15.0 (Chicago, IL). To assess the 
efficacy of NS intervention, statistical evaluation focused on comparisons among 
different treatment levels and different time points. Since urinary AFM1 levels were not 
normally distributed, the Kruskal-Wallis test or Wilcoxon rank sum test were used for 
comparisons. To evaluate the effect of dose-time interactions on NS treatment, a 
nonparametric mixed-effect model was applied, as described by Brunner et al. (2002). 
This ranking is based on a method in the repeated measurement design, in which the 
significance of dose, time, and dose–time effects are determined by a non-parametric 
marginal effects approach to derive the analysis of variance-type statistics and establish 
the distribution of the estimated relative effects when the null hypothesis is not true. A p-
value ≤ 0.05 (two-tailed) was considered significant.   
2.3 Results 
2.3.1 Dioxins/furans and metal analyses in NovaSil clay   
 Among the USEPA priority PCDDs/PCDFs, 1,2,3,4,6,7,8-heptachlorodibenzo-p-
dioxin (HpCDD) and 1,2,3,4,6,7,8,9-octachlorodibenzo-p-dioxin (OCDD) were the only 
contaminants present above the limits of detection (LODs = 1.11 parts per trillion, ppt 
for HpOCDD and 1.91 ppt for OCDD). The mean concentrations of HpCDD and OCDD 
in NS (1.0 g) were 4.42 and 23.74 ppt, respectively. The toxic (or TCDD) equivalency 
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(TEQ) values of these dioxins were calculated to be 0.0442 and 0.00237 ppt for HpCDD 
and OCDD, respectively, with a combined TEQ of 0.0466 ppt. Thus, the HD treatment 
(3.0 g NS/day) provided a TEQ of 0.1397 pg/day. According to standards set by the 
World Health Organization (WHO), the tolerable human intake (THI) of TCDD is 2.3 
pg/kg BW/day, which is calculated to be 161 pg/day for a 70 kg man and 138 pg/day for 
a 60 kg woman (developed by WHO, reported by Van den Berg et al. 1998). Based on 
these values, the TEQ from 3.0 g NS would be considerably lower (by ~1000 times) than 
the daily WHO-THI standards. In addition, all metals calculated to be in 3.0 g NS were 
considerably lower than the JECFA standard recommended values (Table V).   
 
 
 
Table V. Trace metal levels calculated in NS clay. 
 
Trace metal Concentration in NS (mg/kg) 
Amount in 3.0 g NS 
(mg)a 
JECFA value 
(mg/day)b 
Arsenic (As) 2.23 0.0067 0.150 
Cadmium (Cd) 0.260 0.0008 0.060 
Chromium (Cr) 1.12 0.0034 0.250 
Cobalt (Co) 1.36 0.0041 0.016 
Lead (Pb) 10.3 0.0310 0.210 
Mercury (Hg) ND ND 0.043 
Molybdenum (Mo)  0.150 0.0005 0.110 
Nickel (Ni) 2.82 0.0085 0.300 
Selenium (Se) 0.500 0.0016 0.057 
Strontium (Sr) 1430 4.2900 5.000 
Zinc (Zn) 66.9 0.2008 45.00 
 
aDerived dose of metals in 3.0 g NS (assuming bioavailability of total metal concentration); 
bTolerable daily human intake of metals from foods based on Joint FAO/WHO Expert 
Committee on Food Additives (JECFA) recommendations (1998). ND = non-detectable.  
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2.3.2 Participant adherence to the study protocol and sample collection  
 A total of 180 participants were selected from 507 screened volunteers based on 
predetermined inclusion criteria. Three of the selected subjects (1 from the LD group 
and 2 from the PL group) were removed from the study prior to intervention since two 
females became pregnant and one male opted out because of a new job. Therefore, 177 
individuals comprised our study population. Table VI delineates the demographic 
characteristics of the subjects enrolled in the study.  
 
 
 
 
Table VI. Demographic characteristics of study participants in Ghana.  
 
Treatment group 
Demographic characteristics 
Placebo Low dose High dose 
Participants 58 59 60 
Gender    
      Male  37 31 34 
      Female 21 28 26 
Community     
      Dromankoma 20 12 13 
      Ejura Group 9 8 10 
      Nkwanta 5 8 6 
      Hiawoanwu 12 15 18 
      Kasei 3 5 3 
      Kotokoli Line 9 11 10 
Age (year)a 36.5 ± 10.8 37.3 ± 11.8 38.6 ± 13.0 
   
 a Data are presented as mean ± SD. 
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 A total of 162 subjects (91.5%) completed the 3-month trial. Data representing 
study completion and participant compliance are summarized in Table VII. The overall 
adherence (number of times capsules were taken) among the participants, whether or not 
they completed the study, was over 97%.  
 
 
 
Table VII. Participant compliance and completion of treatment regimen. 
  
Treatment group 
 
Placebo Low dose High dose Overall 
Participants     
     Started 58 59 60 177 
     Completed (3 months) 55 53 54 162 
     Completion (%) 94.8% 89.8% 90.0% 91.5% 
Treatment regimen     
    Times Capsule taken 15035 14697 14847 44579 
    Times Capsule missed 220 543 390 1153 
    Total reported 15255 15240 15237 45732 
    Adherence (%) 98.6% 96.4% 97.4% 97.5% 
 
 
 
2.3.3 Urinary aflatoxin M1 levels 
 Among the four time points of sample collection, ≥ 90% of urine samples were 
collected from participants, indicating valid sample numbers for final statistical 
evaluation (Table VIII). A total of 624 urine samples over the study period were 
analyzed for AFM1. About 87% of the samples had detectable levels and no significant 
difference was found in detection rate among three study groups. Mean ± SD and 
median levels of AFM1 at baseline and following intervention are presented in Table IX. 
  
 
 
 
Table VIII. Sample information for each collection time in each  
treatment arm in NS intervention study in Ghana. 
 
Number of urine samples collecteda 
Treatment group 
Baseline 1-month 3-month 4-month 
Placebo 53 (4) 52 (4) 54 (8) 55 (7) 
Low dose 53 (9) 53 (9) 51 (9) 43 (2) 
High dose 53 (6) 52 (6) 53 (10) 52 (10) 
 
a Valid number of samples collected from study participants at each time point (non-detectable AFM1). 
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Table IX. Levels of urinary aflatoxin M1 in study participants in Ghana  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aflatoxin M1 levels (pg/mg creatinine)a Treatment group 
Baseline 1-month 3-month 4-month 
Placebo 
53.42 
644.22 ± 2026.53 
(0.89 - 13297.67) 
24.58 
94.71 ± 160.13 
(1.66 - 798.11) 
52.38 
181.26 ± 675.90 
(2.02 - 5006.37) 
17.32 
56.84 ± 110.14 
(0.04 - 529.41) 
Low dose 
45.54 
183.58 ± 334.96 
(0.66 - 1547.39) 
34.19 
202.06 ± 639.73 
(0.46 - 4338.52) 
51.17 
307.08 ± 1248.35 
(1.59 - 8878.78) 
32.87 
358.59 ± 1594.00 
(2.87 - 10510.81) 
High dose 
60.27 
256.30 ± 615.17 
(0.69 - 3901.90) 
20.99 
175.09 ± 818.41 
(0.70 - 5882.71) 
21.61* 
67.31 ± 102.54 
(0.80 - 411.68) 
12.22 
70.39 ± 155.68 
(0.39 - 873.72) 
 
aData are presented as median, mean ± SD (detectable range). * p < 0.05 as compared with placebo and 
low dose groups. 
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2.3.4 Effect of NovaSil intervention on aflatoxin M1 levels 
Since the data were highly variable, non-parametric analysis was applied for 
statistical evaluations. The distribution of urinary AFM1 levels in the three treatment 
arms throughout the study duration is shown in Figures 15 and 16. No significant 
differences were found in median AFM1 levels among the three study groups at baseline 
(p = 0.2485). Furthermore, no significant differences were found in median AFM1 levels 
among the three groups 1-month after the NS intervention (p = 0.3342). Statistically 
significant differences were observed after 3-months of NS intervention (p = 0.0445). 
While the median AFM1 level was comparable between the PL group and the LD group 
(p = 0.3951), a reduction rate of 58.7% in the median AFM1 level was found between the 
HD group and the PL group (p = 0.0391) at this time point. A reduction rate of 57.8% in 
median AFM1 was also found between the HD group and the LD group (p = 0.0219). 
Significant differences in median AFM1 levels (p = 0.0024) were also found among the 
three study groups 1-month post intervention, but was mainly due to higher AFM1 levels 
in the LD group. As shown in Figure 16, significant decreases in AFM1 levels were seen 
in the HD group over the 4-month study period, showing a significant time effect (p = 
0.009). Although a significant time effect was also noticed in the PL group (p = 0.002), 
levels of AFM1 were highly variable, as shown by higher median levels at baseline and 
3-months compared to the lower median levels at 1-month and 4-months. No significant 
time effect for AFM1 levels was found in the LD group over the 4-month study period (p 
= 0.3277).  
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Figure 15. Time effects of NS intervention on AFM1 levels over the study duration. The box 
represents values ranging from 25 to 75 percentile of the total samples, the line within it 
indicating the median value. The bars on both sides of a box represent values ranging from 5 to 
25 percentile and from 75 to 95 percentile, respectively. 
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Figure 16. Dose effects of NS intervention on AFM1 levels over the study duration. The box 
values ranged from 25 to 75 percentile of the total samples, the line within it indicating the 
median value. The bars on both sides of a box represent values ranging from 5 to 25 percentile 
and from 75 to 95 percentile, respectively. 
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Importantly, non-parametric mixed-effect model analysis showed a significant dose-time 
interaction (p = 0.0495) delineating a reduction in urinary AFM1 levels attributable to 
NS intervention. 
2.4 Discussion  
It has been well documented that AFs are ubiquitous, naturally-occurring 
contaminants in a variety of food products. Avoiding consumption of AF-contaminated 
foods is one of the most fundamental approaches for reducing exposure; however, this 
approach is not feasible for many populations in developing countries where food 
security is an issue. Thus, a need for viable intervention strategies to manage AF-
contaminated diets persists. Safety and efficacy are the two most important criteria for 
assessing potential therapeutic and/or clinical intervention agents. The safety of NS has 
been well documented in animals at levels up to 2.0% in the diet (Phillips et al. 2002, 
2006; Afriyie-Gyawu et al. 2005a). Details on the safety of NS intervention in this 3-
month trial have been published separately (Afriyie-Gyawu et al. 2008a). Safety data 
demonstrated daily administration of 1.5 g and 3.0 g NS clay did not produce any dose-
dependent adverse effects or differences in hematological parameters, liver and kidney 
function or electrolytes. The primary aim of this objective was to determine the efficacy 
of NS for reducing AF exposure in humans. In this study, high levels of urinary AFM1 
were observed in study participants at baseline (before NS intervention) confirming 
previous data from four of the six communities that comprised our study population 
(Jolly et al. 2006). In that report levels of AFM1 were highly variable, similar to this 
study in which AFM1 values ranged form undetectable to 13.3 ng/mg creatinine. 
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Variations in urinary AFM1 levels have also been observed in other human populations 
in Africa and China (Allen et al. 1992; Diallo et al. 1995; Jonsyn-Ellis et al. 2000; Wang 
et al. 2001b). This may be attributed to the short-term nature of the AFM1 metabolite 
(i.e., 24 to 48 hours), as well as genotypic or phenotypic variations in AF-metabolizing 
enzymes. A significant time-dependent effect over the course of the study period (i.e., 
the 3-month intervention and 1-month post-intervention) was observed in two of the 
three study groups, e.g., the HD and PL groups, which may reflect variations in seasonal 
AF exposure levels. Nevertheless, findings from this study showed that administration of 
NS at 3.0 g/day over a period of 3-months significantly reduced AFM1 levels (Figure 
15). Furthermore, a significant dose-time interaction demonstrated a reduction in urinary 
AFM1 levels attributable to NS intervention. This confirms earlier work showing NS 
inclusion in the diet reduced levels of AFM1 in the milk of dairy cows (Harvey et al. 
1991b) and diary goats (Smith et al. 1994) and in the urine of rats (Sarr et al. 1995; 
Mayura et al. 1998), turkeys (Edrington et al. 1996), and dogs (Bingham et al. 2004). 
The reduction rate of up to 58.7% in the median AFM1 level of the HD treatment group 
versus the PL group is comparable with an overall 55% reduction observed in median 
urinary levels of AFB1-N7-guanine (a short-term biomarker like AFM1) after 3-month 
intervention with chlorophyllin (Egner et al. 2001). In addition, our reduction rate was 
similar to that observed after 5-weeks of weekly administration of 500 mg oltipraz, a 
chemopreventive agent, which resulted in a 51% reduction of urinary AFM1 levels 
(Wang et al. 1999). However, in that study no significant differences in AFM1 levels 
were observed in the arm receiving 125 mg of oltipraz daily. Unlike the enterosorption 
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strategy which reduces the external dose of toxin prior to adsorption and metabolism, 
chemoprevention involves a reduction in the biologically effective dose of toxin to cells 
by modulating cellular metabolism. Hence, a difference was observed between 
intermittent, high-dose and sustained low-dose oltipraz treatment. In our study, a 
concurrent reduction in serum AFB1–lysine albumin adduct levels (measured at Texas 
Tech University) was observed 3-months after NS intervention (Wang et al. 2008). This 
signifies that intervention with NS clay can effectively reduce AF exposure from 
contaminated diets, as represented by AF-specific biomarkers in both the blood and 
urine. This is the first study to show NS is an effective enterosorbent in the diet of 
humans, suggesting its potential use in populations at high risk for aflatoxicosis.  
In addition to being safe and effective, strategies should be sustainable, 
economically practical, and cultural acceptable. Clay-based enterosorption with NS 
represents a sustainable strategy for the reduction of AF exposure, evidenced by 
participants’ excellent adherence to the treatment regimen (over 97%) and number of 
subjects completing the study (>90%) (Table VII). Additionally, geophagy (clay-eating) 
is common in cultures of sub-Saharan Africa. Women often consume clay during 
pregnancy, reportedly at high levels that may range from 30 to 50 g/day (Wiley and 
Solomon 1998; ATSDR 2000). Thus, NS inclusion in the diet is considered culturally 
acceptable and in the future may be an important vehicle for the protection of developing 
fetuses and young infants against AFs. This Phase IIa intervention trial provides the 
basis for future long-term (phase IIb or III) studies to evaluate the safety and efficacy of 
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NS as an enterosorbent therapy for acute AF exposure and for the prevention of chronic 
AF-induced disease or cancer.   
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III. NOVASIL CLAY INTERVENTION IN A GHANAIAN POPULATION AT 
HIGH RISK FOR AFLATOXICOSIS: LACK OF INTERACTION WITH 
SERUM NUTRIENT MINERALS* 
 
3.1 Introduction  
 Given the anti-nutritional effects of AFs in animals and humans, it is important 
that enterosorbent strategies aimed at managing AF-induced disease do not significantly 
interfere with physiological levels of important vitamins or micronutrients. This is 
especially important in developing countries where individuals may be chronically 
exposed to uncontrolled amounts of AF and nutritional deficiencies are common 
(Williams et al. 2004). Dietary inclusion of NS clay (also referred to as HSCAS) has 
been shown to be safe in over 30 animal models (Table IV). Studies have also indicated 
that NS addition does not affect levels of vitamins or micronutrients (except in one case 
in poultry which suggested Zn utilization may be slightly impaired). Here, authors 
reported that inclusion of HSCAS at 0.5 or 1.0% for 14 days in the diet of broiler chicks 
did not impair utilization of vitamin A, riboflavin, P or Mn; however, total tibia Zn was 
reduced in the presence of 1.0% clay indicating Zn may be affected, albeit only slightly, 
at the highest level of addition (Chung et al. 1990; Chung and Baker 1990). Conversely, 
Southern et al. (1994) investigated the influence of HSCAS inclusion at 0.5% in chicks 
fed nutrient-deficient diets and found no effect on tibia mineral concentrations, including 
                                                 
* Reprinted with permission from “NovaSil clay does not affect the concentrations of vitamins A and E 
and nutrient minerals in serum samples from Ghanaians at high risk for aflatoxicosis” by Afriyie-Gyawu 
E, Wang Z, Ankrah NA, Xu L, Johnson NM, et al. 2008b. Food Addit Contam 25:872–884, Copyright 
[2008] by Taylor & Francis. 
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Zn, Mn, P, and Ca. Still, Chung’s finding that Zn may be possibly affected at high levels 
of montmorillonite inclusion called for the careful observation of the impact of NS on 
micronutrients. Thus, future in vivo studies investigated serum or tissue concentrations 
of vitamins and minerals following NS treatment. For instance, Pimpukdee et al. (2004) 
confirmed earlier findings showing NS treatment alone at three different levels (0.125, 
0.25, and 0.5%) did not affect vitamin A levels. Moreover, NS (as low as 0.25%) 
preserved the levels of hepatic vitamin A in groups exposed to high levels of AFB1 (5 
mg/kg), verifying that NS can ameliorate the adverse effects of AF exposure. Further 
experiments in Sprague-Dawley (S-D) rats demonstrated dietary inclusion of NS clay 
did not affect any serum vitamin or micronutrient levels. For example, in dams fed NS 
throughout pregnancy at levels up to 2.0% (w/w), no significant changes occurred in 
trace metal bioavailability in a variety of maternal and fetal tissues (Wiles et al. 2004). 
Additionally, in a chronic study S-D rats fed NS at levels ranging from 0.25 – 2.0% 
(w/w) over 6.5-months did not exhibit any significant dose-dependent differences in 
concentrations of hepatic vitamin A and E or serum levels of Fe, Zn and vitamins A and 
E compared to controls (Afriyie-Gyawu et al. 2005a). Based on the safety of NS shown 
in these S-D rat studies and in a phase I adverse events trial, the first phase IIa clinical 
intervention trial with NS clay was conducted (described in detail in section II). The high 
dose (HD) group in this study received 0.25% NS in the diet, representing the minimally 
effective dose. Of note, no interactions with vitamins or nutrients have been cited at this 
level in animal models. Therefore, the primary aim of this portion of the study was to 
investigate interactions of NS with important nutrient minerals by measuring serum 
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concentrations before and after clinical intervention. In addition, levels of non-nutrient 
minerals were also evaluated.   
3.2 Materials and methods  
3.2.1 Samples, chemicals, and reagents 
 Selected serum samples collected previously from participants in the Phase IIa 
intervention study were shipped to TAMU frozen and stored at -80°C. Sera from 60 
individuals in the HD (n = 29) and PL (n = 31) groups collected at baseline and 3-
months after intervention were available for mineral analysis. Therefore, concentrations 
of nutrient and non-nutrient minerals were determined in a total of 120 samples (60 
baseline; 60 3-month). Sample digestion and trace element analysis was conducted at the 
Trace Element Research Laboratory at TAMU (College Station, TX). This laboratory 
supplied standard reference materials (Seronorm, Billingstad, Norway) to ensure batch-
to-batch consistency. All other chemicals and reagents were purchased commercially at 
the highest degree of purity available. 
3.2.2 Analysis of nutrient and non-nutrient minerals in serum 
 Approximately 0.45 g of each sample was mixed with 200 µl of concentrated 
nitric acid in a 15 ml centrifuge tube and heated overnight at 90°C. After samples were 
cooled, 100 µl of 30% H2O2 was added and samples were heated at 70°C for 1 hour. 
Following cooling, concentrated hydrochloric acid (50 µl) was added and samples were 
heated at 70°C for 1 hour and cooled. Samples were brought to a final volume of 10 ml 
with purified water. Mercury (Hg) concentrations were determined by cold vapor atomic 
absorption (CVAA) using an M-7500 (Cetac Technologies, Omaha, NE) with stannous 
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chloride as a reductant. Aluminum (Al), barium (Ba), beryllium (Be), calcium (Ca), 
cobalt (Co), copper (Cu), iron (Fe), potassium (K), magnesium (Mg), molybdenum 
(Mo), sodium (Na), phosphorus (P), sulfur (S), strontium (Sr), titanium (Ti), vanadium 
(V), and zinc (Zn) were determined with an inductively coupled plasma-  optical 
emission spectrometer (ICP-OES) using a CirOS (Spectro Analytical Instruments, 
Fitchburg, MA) with axial viewing and ytterbium (Yb) as an internal standard. Silver 
(Ag), arsenic (As), cadmium (Cd), chromium (Cr), manganese (Mn), nickel (Ni), lead 
(Pb), selenium (Se), and thallium (Tl) were determined with an inductively coupled 
plasma-mass spectrometer (ICP-MS) using an Elan 6100 (Perkin-Elmer, Wellesley, MA) 
with As, Cr, Mn, and Se acquired in DRC mode, and bismuth (Bi), gallium (Ga), and 
rhodium (Rh) as internal standards. In addition to blanks, spiked blanks, duplicate 
samples, and spiked samples, results were validated by preparing and analyzing standard 
reference materials with each batch of samples. 
3.2.2 Statistical analysis 
 All data sets generated were stored in an Excel database and analyzed with SPSS 
software version 15.0 (Chicago, IL). Mean, median, and standard deviations (SD) were 
calculated for concentrations of serum minerals, which were grouped into nutrient or 
non-nutrient minerals. Comparison of the mineral components in the HD and PL groups 
at baseline and 3-months following intervention was performed using a student’s t-test 
or the Wilcoxon rank sum test depending on normality. To evaluate the effects of dose, 
time, and the dose–time interactions of NS treatment on levels of the trace elements, a 
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non-parametric mixed-effect model was applied as previously described (Brunner et al. 
2002). A p-value of ≤ 0.05 (two-tailed) was considered statistically significant. 
3.3 Results 
A total of 120 serum samples, collected from participants in the HD and PL 
groups at baseline and 3-months were used for the mineral analyses. The serum levels of 
30 minerals were grouped into two categories, nutrient (15) and non-nutrient (15), and 
are represented in Tables X and XI. In the gender-stratified nutrient category (Table X), 
baseline levels of each of the 15 minerals measured in the HD and PL groups were not 
significantly different in male and female participants. Furthermore, no statistically 
significant differences were found in levels of these nutrient minerals between the HD 
and PL groups at the end of the 3-month intervention trial. With respect to the 15 non-
nutrient minerals analyzed (Table XI), there were no significant differences in any 
mineral at the baseline between HD and PL groups. After 3-month NS intervention, only 
levels of strontium (Sr) in serum were significantly different between the PL and HD 
groups (p < 0.001) in both males and females. In the 3-month samples, serum Sr levels 
were significantly higher in the HD group (113.65 ± 28.00 µg/L) as compared with the 
PL group (83.55 ± 39.90 µg/L) in males and in females with levels in the HD group 
(116.40 ± 24.26 µg/L) versus the PL group (90.47 ± 25.68 µg/L). No significant gender 
difference in serum Sr levels was found. Gender-adjusted non-parametric mixed-effect 
model analysis showed a significant dose (p = 0.0214), time (p = 0.0000), and dose*time 
(p = 0.0000) effect for serum Sr indicating increased levels may be attributable to NS 
intervention. No other significant dose*time effects were noted for minerals.   
 Table X. Serum levels of nutrient minerals in study participants in Ghana at baseline and 3-months of intervention. 
Baseline 3-Months 
Male Female Male Female 
Nutrient 
minerals Placebo High dose Placebo High dose Placebo High dose Placebo High dose 
Ca (mg/L) 90.28 ± 4.28 93.84 ± 4.58 93.18 ± 4.25 90.29 ± 5.48 93.72 ± 7.58 97.00 ± 4.79 95.63 ± 6.42 93.90 ± 5.72 
Cu (mg/L) 1.12 ± 0.19 1.32 ± 0.27 1.41 ± 0.30 1.66 ± 0.42 1.14 ± 0.16 1.27 ± 0.25 1.38 ± 0.22 1.36 ± 0.16 
Fe (mg/L) 1.29 ± 0.42 1.23 ± 0.30 1.45 ± 1.14 1.36 ± 0.43 1.40 ± 0.57 1.33 ± 0.32 1.23 ± 0.32 1.31 ± 0.51 
K (mg/L) 220.42 ± 23.00 219.10 ± 25.62 224.83 ± 27.89 207.70 ± 17.58 189.00 ± 19.38 195.32 ± 17.65 196.67 ± 24.08 190.00 ± 16.69 
Mg (mg/L) 18.72 ± 1.20 18.57 ± 1.68 18.09 ± 1.62 17.59 ± 1.75 19.85 ± 1.97 19.32 ± 1.31 19.42 ± 1.71 19.08 ± 2.06 
Na (mg/L) 3097.90 ± 71.61 3130.53 ± 61.87 3121.67 ± 79.07 3100.00 ± 95.92 3160.00 ± 164.76 3205.79 ± 64.32 3184.17 ± 168.12 3185.00 ± 141.52 
P (mg/L) 106.54 ± 6.89 107.51 ± 15.07 117.96 ± 13.90 105.35 ± 12.38 112.02 ± 13.24 115.98 ± 19.67 121.66 ± 16.13 111.50 ± 11.72 
S (mg/L) 1197.90 ± 60.33 1244.74 ± 76.26 1241.67 ± 97.50 1216.00 ± 78.34 1253.68 ± 136.27 1287.37 ± 73.09 1303.33 ± 112.44 1268.00 ± 81.62 
Zn (mg/L) 1.37 ± 0.57 1.21 ± 0.12 1.20 ± 0.28 1.36 ± 0.65 1.38 ± 0.40 1.38 ± 0.33 1.31 ± 0.23 1.25 ± 0.54 
Co (µg/L) 1.36 ± 0.78 1.30 ± 0.85 1.06 ± 0.38 1.77 ± 1.71 1.65 ± 1.07 1.35 ± 0.88 1.21 ± 0.47 0.95 ± 0.20 
Cr (µg/L) 7.84 ± 11.89 4.66 ± 0.48 6.12 ± 2.62 8.31 ± 10.41 6.50 ± 3.92 6.19 ± 3.61 4.68 ± 0.52 7.25 ± 3.50 
Mn (µg/L) 8.35 ± 8.28 4.64 ± 4.42 4.95 ± 5.59 4.38 ± 2.14 9.13 ± 13.90 5.37 ± 3.39 2.94 ± 0.87 3.77 ± 1.51 
Mo (µg/L) 14.97 ± 5.06 17.04 ± 3.94 17.07 ± 4.22 16.59 ± 5.84 23.73 ± 11.58 20.40 ± 6.48 23.52 ± 18.74 21.32 ± 9.12 
Ni (µg/L) 18.47 ± 2.61 16.25 ± 2.98 17.61 ± 4.24 21.18 ± 17.80 19.39 ± 5.59 19.08 ± 9.06 16.14 ± 2.94 16.51 ± 3.36 
Se (µg/L) 111.87 ± 2 0.01 113.94 ± 23.67 123.13 ± 23.50 122.17 ± 20.96 122.80 ± 22.18 121.33 ± 26.28 128.92 ± 16.40 128.87 ± 28.71 
 
Note: Data represent the mean ± SD of the serum levels of trace elements. After 3-months of NS intervention, no significant 
differences were found in the HD group compared to PL group in both male and female participants (p > 0.05). 
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 Table XI. Serum levels of non-nutrient minerals in study participants in Ghana at baseline and 3-months of intervention. 
 
Baseline 3-Months 
Male Female Male Female Non-
nutrient 
minerals Placebo High dose Placebo High dose Placebo High dose Placebo High dose 
Ag (µg/L) 0.23 ± 0.02 0.22 ± 0.01 0.25 ± 0.07 0.23 ± 0.02 0.33 ± 0.48 0.22 ± 0.01 0.22 ± 0.01 0.24 ± 0.06 
Al (µg/L) 146.84 ± 63.24 120.58 ± 55.05 105.42 ± 43.48 157.90 ± 122.94 133.53 ± 66.54 134.58 ± 71.70 98.17 ± 38.00 153.80 ± 111.88 
As (µg/L) 8.64 ± 1.39 9.27 ± 1.77 8.38 ± 1.01 8.91 ± 1.28 8.78 ± 2.28 8.98 ± 1.28 8.09 ± 1.09 8.30 ± 1.21 
Ba (µg/L) 79.74 ± 11.90 83.16 ± 10.32 74.75 ± 17.22 81.20 ± 24.54 122.05 ± 24.42 112.74 ± 18.13 108.42 ± 44.53 119.30 ± 51.27 
Be (µg/L) 1.13 ± 0.10 1.11 ± 0.03 1.10 ± 0.02 1.12 ± 0.03 1.11 ± 0.05 1.10 ± 0.03 1.10 ± 0.03 1.19 ± 0.29 
Cd (µg/L) 0.63 ± 0.16 0.78 ± 0.60 0.71 ± 0.20 0.67 ± 0.30 0.72 ± 0.36 0.74 ± 0.58 0.69 ± 0.17 0.63 ± 0.17 
Hg (µg/L) 5.63 ± 0.50 5.55 ± 0.16 5.48 ± 0.08 5.59 ± 0.16 5.55 ± 0.24 5.18 ± 0.16 5.51 ± 0.14 5.95 ± 1.43 
Li (µg/L) 22.63 ± 1.86 22.16 ± 0.60 21.91 ± 0.29 22.40 ± 0.70 22.21 ± 0.98 22.00 ± 0.67 21.92 ± 0.67 23.90 ± 5.69 
Pb (µg/L) 17.53 ± 7.02 15.12 ± 8.57 13.70 ± 6.03 18.32 ± 13.04 15.67 ± 4.39 14.05 ± 4.84 18.02 ± 18.43 12.10 ± 6.00 
Sb (µg/L) 1.13 ± 0.10 1.11 ± 0.03 1.10 ± 0.02 1.12 ± 0.03 1.14 ± 0.17 1.10 ± 0.03 1.10 ± 0.03 1.19 ± 0.29 
Sr (µg/L) 70.15 ± 16.48 68.01 ± 16.54 75.70 ± 27.45 75.68 ± 12.33 83.55 ± 39.90 113.65 ± 28.00** 90.47 ± 25.68 116.40 ± 24.26** 
Ti (µg/L) 112.68 ± 9.87 111.10 ± 3.11 109.67 ± 1.50 111.80 ± 3.33 110.84 ± 4.68 110.37 ± 3.18 110.25 ± 2.80 118.90 ± 28.61 
Tl (µg/L) 0.23 ± 0.03 0.22 ± 0.01 0.26 ± 0.09 0.26 ± 0.09 0.30 ± 0.35 0.22 ± 0.01 0.23 ± 0.04 0.24 ± 0.06 
U (µg/L) 0.28 ± 0.21 0.22 ± 0.01 0.22 ± 0.01 0.22 ± 0.01 0.22 ± 0.01 0.22 ± 0.01 0.23 ± 0.04 0.24 ± 0.06 
V (µg/L) 11.27 ± 0.99 11.11 ± 0.31 10.97 ± 0.15 11.18 ± 0.33 11.08 ± 0.47 11.04 ± 0.32 11.03 ± 0.28 11.89 ± 2.86 
77 
Note: Data represent the mean ± SD of the serum levels of trace elements. After 3-months of NS ingestion, only Sr 
levels were significantly higher ** p < 0.001 in the HD versus PL groups in both male and female participants.
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3.4 Discussion  
 In the past, it has been suggested that the positive charge deficiencies on 
phyllosilicate clays create potential for sorption of positively charged or cationic 
compounds, including minerals (Theng 1974). In fact, this mechanism may be partly 
responsible for the adsorption of AFB1 onto NS surfaces. Conversely, interference with 
micronutrients may hinder the use of enterosorption for the reduction of AFs. Therefore, 
to further ensure the safety of NS administration, we investigated the potential for NS to 
interfere with vitamins and minerals in participants in our clinical trial in Ghana. Details 
on the effect of NS intervention on serum vitamin A and E levels have been described 
separately (Afriyie-Gyawu et al. 2008b). Data demonstrated that daily administration of 
1.5 g and 3.0 g NS clay did not produce any dose-dependent adverse effects or 
differences in concentrations of these two important vitamins. Results from this portion 
of the study clearly illustrate that administration of NS clay at the high dose level over a 
period of 3-months did not affect the serum concentrations of nutrient minerals, 
evidenced by comparable levels of these parameters among the HD and PL groups in 
males and females (Table X) at both time-points. Importantly, these findings confirm the 
results of our previous short-term human study (Wang et al. 2005) and numerous animal 
studies (Wiles et al. 2004; Afriyie-Gyawu et al. 2005a). Furthermore, concentrations of 
non-nutrient minerals, with the exception of Sr, did not differ significantly between 
groups at baseline or 3-months with NS treatment. Overall, these findings reflect the 
purity of the test agent and our efforts to minimize potential environmental toxicants and 
non-nutrient minerals in NS. For instance, priority metals were either below the LOD for 
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the analytical procedures used, or present in the HD at levels 7- to 240-fold lower than 
the JECFA standards (Table V). Data also suggest that mineral components in NS are 
largely unavailable for absorption. However, serum Sr levels were statistically increased 
in the HD group compared to the PL group at 3-months of NS intervention in both 
genders, implying bioavailability of this mineral. These data are in agreement with 
previous Phase I results which showed an apparent dose-dependent increase in serum Sr 
after 2-week NS intake in participants from the U.S. (Wang et al. 2005). Since clinical 
reference ranges are currently not available for serum Sr, it is challenging to interpret the 
significance of this effect on a clinical basis. Sr is naturally present in water and foods, 
such as cereals, grains and seafood at levels up to 25 mg/kg (Cabrera et al. 1999). 
Naturally-occurring Sr, other than its radioactive isotope, is considered non-hazardous. 
Sr is similar to Ca in that these minerals are absorbed in the GI tract, concentrated 
mainly in the bone, and primarily excreted in the urine (Cohen-Solal 2002). In a clinical 
trial for treatment of osteoporosis, up to 680 mg Sr/day did not result in significant 
adverse effects in human volunteers (Meunier et al. 2004). In the present study, the 
amount of Sr calculated to be in 3.0 g NS (the HD level) was equal to 4.29 mg/day. This 
is considerably lower than levels found in certain foods and drastically lower than levels 
administered in the osteoporosis intervention trial. Thus, it is not anticipated that this 
level would be of any clinical significance to participants. Still, in future studies we 
intend to closely monitor physiological levels of Sr in addition to vitamin and mineral 
concentrations. Overall, these results in combination with to findings presented in 
Section II indicate that NS intervention (up to 3.0 g/day) is safe and effective, supporting 
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the prospect of applying NS for the protection humans who are either acutely or 
chronically exposed to high levels of AFs in their diet.  
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IV. ASSESSMENT OF PAH EXPOSURE IN A GHANAIAN POPULATION AT 
HIGH RISK FOR AFLATOXICOSIS* 
 
4.1 Introduction  
 In the Ashanti Region of Ghana, our previous biomarker data have shown 
individuals are at high risk for aflatoxicosis based on levels of AF exposure biomarkers 
measured in the blood and urine (Jolly et al. 2006; section II). It is also well-known that 
chronic AF exposure significantly contributes to the risk of developing liver cancer 
(Wogan 1992; IARC 1993), and in West Africa HCC risk is significantly increased by 
chronic infection with hepatitis B virus (HBV) (Kao and Chen 2002). While population-
based cancer morbidity and mortality data in Africa on the whole are scarce to non-
existent, as early as the 1950s, researchers noted primary liver carcinoma was common 
in West African troops (Findlay 1950; Edington 1956). Since Edington’s report, cancer 
mortalities were largely undocumented in Ghana until a recent review article by Wiredu 
and Armah (2006). In this report authors reviewed cancer mortality patterns in Ghana 
based on autopsies and hospital records from the previous 10 years and showed liver 
cancer was the leading cause of cancer death in men and third leading cause in women. 
This is consistent with reports from other geographic regions where chronic AF 
exposure and HBV infection persist, particularly in China, Taiwan, and other parts of 
Africa (Kirk et al. 2006). Since it has been proposed that a concurrent exposure to PAHs 
                                                 
* Reprinted with permission from “PAH Exposure in a Ghanaian population at high risk for aflatoxicosis” 
by Johnson NM, Afriyie-Gyawu E, Huebner HJ, Marroquin-Cardona A, Robinson A, et al. 2009. Sci Total 
Environ 407:1886–1891, Copyright [2008] by Elsevier.  
 82
may interact with known risk factors for HCC, e.g., AF and HBV (Wu et al. 2007), it 
was of interest to determine PAH exposure in our well-defined study population in 
Ghana. Although some published studies have determined PAH concentrations in soil 
and water matrices (Essumang et al. 2006; Tano-Debrah et al. 2007), no direct 
biomarker measurements for human exposure to PAHs have been reported in Ghana to 
our knowledge. Therefore, the main objectives of this portion of the study were to assess 
overall exposure to PAHs by measuring urinary 1-hydroxypyrene (1-OHP) and to 
determine if there was a relationship between AF and PAH exposures. Since concurrent 
exposures may affect HCC risk, strategies that reduce AFs and PAHs are highly 
desirable for populations at risk for both agents. Among various strategies, clay-based 
enterosorption by NovaSil (NS) appears to be safe and effective for the reduction of AFs 
(Afriyie-Gyawu et al. 2008a, 2008b; Wang et al. 2008). The enterosorption strategy 
would not be expected to reduce PAH exposure from inhalation; however, the potential 
affect of NS on the bioavailability of PAHs from the gastrointestinal tract has not been 
investigated. Thus, a secondary objective was to determine the effect of NS versus PL 
treatment on 1-OHP levels in urine samples collected from the NS intervention trial. 
4.2 Materials and methods  
4.2.1 Chemicals and reagents   
Authentic 1-OHP reference standard was obtained from the Midwest Research 
Institute Chemical Carcinogen Reference Standard Repository (Kansas City, MO). UV-
visible spectrophotometry was used to verify the concentration of 1-OHP stock 
solutions. Sep-Pak C18 cartridges were purchased from Waters (Milford, MA), and β-
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glucuronidase from Helix pomatia (type HP-2S) were obtained from Sigma Chemical 
Co. (St. Louis, MO). All of the experiments were done using filtered and deionized 
water (18.2 MΩ.cm) (Millipore, Milford, MA) and HPLC-grade solvents. All other 
chemicals and reagents were purchased commercially at the highest degree of purity 
available.  
4.2.2 Study design  
The study protocol (previously described in detail in section 2.2.3) was approved 
by the Institutional Review Boards at Texas A&M University and Noguchi Memorial 
Institute for Medical Research in Ghana for Ethical Clearance. To delineate contributing 
factors to PAH exposure, participants were further classified as smokers or non-smokers. 
Trained study monitors collected blood and urine samples from each participant at 
specified time points (Figure 12). Aliquots of the first urines collected were stored 
separately (~4.5 ml) in polypropylene tubes for 1-OHP analysis and shipped to TAMU 
where they were kept frozen at -80°C.  
4.2.3 Urinary 1-hydroxypyrene analysis  
Urinary 1-OHP levels were measured using an HPLC-fluorescence method based 
on a procedure described by Gardiner et al. 1992. Briefly, urine samples (4.0 ml) were 
adjusted to pH 5.0 with an equal volume of 1.0 M acetate buffer (pH 5.0). β-
Glucuronidase (50 μl) from Helix pomatia possessing sulfatase activity was added, and 
samples were incubated for 4 hours at 37°C while gently shaking in a water bath. The 
hydrolyzed samples were passed through primed Sep-Pak C18 columns on a vacuum 
manifold followed by sequential washing steps of 3.0 ml deionized H20 followed by 3.0 
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ml 50% MeOH in water. 1-OHP was eluted from the column with 100% MeOH, and the 
eluates were evaporated to dryness under N2 gas and reconstituted in MeOH. The 
analyses were conducted using an HPLC system with fluorescence detection (Waters, 
Milford, MA). Excitation and emission parameters were set at 240 and 388 nm, 
respectively. Aliquots of the extracts were injected and analyzed using a 125 x 4.6 mm 
Spherisorb ODS2 HPLC column (Waters) with a particle size of 3 μm.  The mobile 
phase was comprised of 75% MeOH in water, and chromatographic separation was 
achieved by isocratic elution at a flow rate of 1.1 ml/min for 15 min. The 1-OHP peak 
was detected at a retention time averaging 6.2 min (Figure 17), and the limit of detection 
was approximately 0.25 nmol/L of urine. Urinary concentrations of 1-OHP were 
expressed as μmol/mol creatinine in order to correct for variations in urine dilution.  
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Figure 17. Representative HPLC chromatograph showing urinary 1-hydroxypyrene metabolite 
peaks. The 1-OHP metabolite in a participant sample collected at baseline (black) is compared to 
a 10 ng/ml 1-OHP standard solution (blue). Peak areas were used for quantification of 1-OHP in 
urine samples collected from at baseline and 3-months of intervention.   
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Blank urines spiked with 1-OHP standard in the range of 0.01 – 2 ng were prepared, 
incubated and extracted as described in the procedure minus the enzyme addition to 
generate a six-point calibration curve that was linear over the tested range (r2 = 0.9904) 
for the instrument. The repeatability precision was 7.0% and recoveries averaged 99%. 
The machine was calibrated daily by injecting multiple aliquots of 1-OHP reference 
standard, which was prepared bi-weekly and stored in the dark at 4°C.   
4.2.4 Statistical analysis   
Data generated from HPLC analysis were transferred into an Excel database for 
management. Mean, median, standard deviation (SD) and range were calculated for 
concentrations of 1-OHP. Statistical analyses were done using SPSS software version 
15.0 (Chicago, IL). Correlation analysis was done to examine the relationship of AF and 
PAH exposures (i.e., AF-albumin adduct compared to 1-OHP levels); p-values were 
generated based on Spearman correlation coefficients. To show the consequence of NS 
ingestion on 1-OHP levels, statistical evaluation focused on the comparisons among 
different treatment groups at baseline and 3-months following intervention. Since the 
parameters were not normally distributed, the Kruskal-Wallis test or Wilcoxon rank sum 
test was used to compare the differences among and between treatment groups at each 
time point. To evaluate the effect of dose and time interactions, a nonparametric mixed-
effect model was applied as previously described (Brunner et al. 2002). A p-value of ≤ 
0.05 (two-tailed) was considered significant.   
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4.3 Results  
4.3.1 Urinary 1-hydroxypyrene levels  
Overall, a total of 279 urine samples collected at baseline (n = 121) and 3-months 
(n = 158) were available for 1-OHP analysis. Out of the total urines, 98.9% showed 
detectable levels of 1-OHP. Median, mean ± SD, and the range of 1-OHP levels at both 
time points are presented in Table XII; participants are further delineated as smokers or 
non-smokers. Only 9 of the 177 study participants were known tobacco-smokers. In non-
smokers, levels of 1-OHP were detected in 98.2% (111/113) and 99.3% (148/149) of the 
samples collected at the beginning of the study (baseline) and following 3-months 
intervention, with median values of 0.64 and 0.69 μmol/mol creatinine, respectively. Of 
the participants classified as tobacco-smokers, 1-OHP was detected in 100% of urine 
samples from baseline (8/8) and 3-months (9/9). Median levels of 1-OHP did not differ 
significantly in participants classified as smokers compared to non-smokers in samples 
measured at baseline (p = 0.098) or after 3-months of intervention (p = 0.822).  
 
 
 
Table XII. Levels of urinary 1-OHP in study participants in Ghana. 
  
1-OHP levels (µmol/mol creatinine)a 
Smoking status Baseline 3-months 
Non-smokers 0.64, 0.80 ± 0.68 (0.01 – 3.37)  
0.69, 1.08 ± 1.09 
(0.06 – 5.11) 
Smokers 0.42, 0.42 ± 0.25 (0.10 – 0.78) 
0.61, 1.00 ± 0.81 
(0.32 – 2.37) 
 
aData are presented as median, mean ± SD (detectable range). 
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4.3.2 Relationship between 1-hydroxypyrene and AF-albumin adduct levels  
Correlation analysis was done to examine the relationship between AF exposure 
(measured by the AF-albumin adduct) and 1-OHP levels; results are illustrated in Figure 
18. No significant correlations were found between levels of the AF-albumin adduct and 
1-OHP at baseline (Figure 18a CC=0.080, p=0.394) or after 3-months of intervention 
(Figure 18b CC=0.029, p=0.717); CC represents Spearman correlation coefficients. 
4.3.3 Effect of NovaSil intervention on 1-hydroxypyrene levels   
 The distribution of urinary 1-OHP levels in participants at baseline and after 3- 
months of intervention is illustrated in Figure 19. There were no significant differences 
in median 1-OHP levels among the three study groups at baseline (p = 0.890) or after 3- 
months of intervention (p = 0.384). The median 1-OHP levels were comparable between 
the PL and LD group in urine samples collected at baseline (p = 0.820) and 3-months (p 
= 0.186). Additionally, no significant differences were found in median levels of 1-OHP 
between the PL and HD group at baseline (p = 0.843) or after 3-months (p = 0.325). 
Furthermore, no significant time effect for 1-OHP levels were found in the HD (p = 
0.373), LD (p = 0.113) or PL (p = 0.758) groups over the 3-month study period (Figure 
20). Non-parametric mixed-effect model analysis did not show a significant dose-time 
interaction (p = 0.436) delineating that there was not a reduction in urinary 1-OHP levels 
due to the NS intervention. A trend for reduction in 1-OHP levels in participants in the 
PL group was observed after 3-month intervention; median 1-OHP values were 0.66 
μmol/mol creatinine at baseline and 0.58 μmol/mol creatinine after 3-months. However, 
this difference was not statistically significant.    
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Figure 18. Correlation analyses between 1-OHP and AF-albumin adduct levels in study participants in Ghana. No significant correlations 
were found between AF-albumin adduct and 1-OHP levels at baseline (a) or after 3-months of intervention (b); p-values were generated 
based on Spearman correlation coefficients (CC).  
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Figure 19. Dose effects of NS intervention on 1-OHP levels over the study duration. The box 
represents values ranging from 25 to 75 percentile, the line within indicates the median value. 
The bars on both sides of the box represent values ranging from 5 to 25 percentile and from 75 to 
95 percentile, respectively. 
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Figure 20. Time effects of NS intervention on 1-OHP levels over the study duration. The box plots show distributions of 1-OHP 
levels in each group at baseline (0-month) and after 3-months of intervention. The box represents values ranging from 25 to 75 
percentile, the line within it indicating the median value. The bars on both sides of the box represent values ranging from 5 to 25 
percentile and from 75 to 95 percentile, respectively. No significant time effect for 1-OHP levels were found in any of the treatment 
arms over the course of the study period. 
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4.4 Discussion  
Findings from this portion of our study illustrated that the majority of study 
participants in Ghana had a measurable exposure to PAHs (Table XII). Data further 
demonstrated 1-OHP levels did not vary significantly between participants classified as 
smokers and non-smokers. The influence of cigarette smoke on 1-OHP levels has 
yielded differing results in previous work. When individuals were exposed to 
background levels of environmental PAHs, the consequence of smoking resulted in 
increased excretion of 1-OHP (Levin et al. 1995; Viau et al. 1995). Conversely, at higher 
exposure levels, smoking failed to produce any differences in urinary 1-OHP levels, 
compared to not smoking (Buchet et al. 1992; Bouchard and Viau 1999; Viau et al. 
2000). In this study, smoking did not show an effect on 1-OHP levels possibly because 
environmental exposure was predominant. In addition, of the small percentage classified 
as smokers in our study population (only 9 subjects), details such as amount and 
frequency of smoking was unknown. This information would be of interest in future 
studies. Nonetheless, 1-OHP levels measured in this Ghanaian population were higher 
than those previously recorded for non-smoking individuals in numerous countries 
(Table III). For instance, the median 1-OHP level measured in non-smokers at baseline 
in our study population (0.64 μmol/mol creatinine) was considerably higher than median 
1-OHP concentrations documented in non-smokers in the U.S. (0.27 μmol/mol 
creatinine), Canada (0.07 μmol/mol creatinine), and other Western European countries 
(Levin 1995). Alternatively, our results were remarkably similar to reported levels of 1-
OHP measured in non-smokers in a Chinese population (median = 0.68 μmol/mol 
 92
creatinine) and comparable, albeit lower, to individuals living in traditional houses in 
rural Burundi (geometric mean = 1.50 μmol/mol creatinine) (Zhao et al. 1995; Viau et al. 
2000). In both reports, authors proposed the increased levels of 1-OHP excretion may be 
attributable to the broad use of coal or wood burning for cooking and heating purposes. 
In fact, the use of indoor wood/coal burning fireplaces and stoves are employed as the 
primary means of cooking and heating in many developing countries, particularly in 
rural areas. It has been documented that the combustion of wood and other fuels for 
cooking constitutes a significant source for PAH exposure (Lioy and Greenberg 1990) 
and, the subsequent consumption of grilled foods has been linked to increased levels of 
1-OHP in the urine (van Maanen et al. 1994). The elevated level of 1-OHP measured in 
our study population and knowledge of cooking culture in this rural area of Ghana 
largely suggests that inhabitants are exposed to high doses of PAHs from the indoor 
preparation of foods by using wood as fuel, socializing by fires, and the ingestion of 
smoked foods.  
 Another possible route of PAH exposure in our study population may be through 
the ingestion of dried/smoked maize. Maize if often dried directly on hot asphalt roads, 
suggesting an additional mode of PAH contamination. The direct drying and smoking of 
this staple crop is regularly employed as the first step in food preparation or as a way to 
decrease mold contamination in storage or repel insects. AF-contaminated maize 
constitutes a major food safety problem in Ghana. Since exposure to both AFs and PAHs 
may result in an even greater risk of significant negative health impacts, we investigated 
the correlation between 1-OHP and AF-albumin levels as a means of indirectly linking a 
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high intake of AF-contaminated food with high PAH exposure. Although 1-OHP is 
considered a short-term biomarker of exposure, measurements at both time-points in our 
study population did not show a significant time-effect. Thus, PAH exposure may be 
assumed to be relatively continuous over this time period. Correlation analyses showed 
that there was not a significant linear correlation between urinary 1-OHP levels and 
serum AF-albumin adducts levels at baseline or 3-months (Figure 18). This is likely due 
to multiple and different pathways of exposure to these compounds. Ultimately, subjects 
exposed to both PAHs and AFs, even if the exposure levels are independently 
distributed, may be at increased risk for disease or possibly HCC. 
 A second objective of this portion of our clinical intervention study was to 
determine the consequence of NS treatment on urinary 1-OHP. To date, no clinical 
interventions have been reported for PAHs using enterosorbent strategies. Results from 
our study illustrated that NS-treatment did not significantly alter 1-OHP levels after 3-
months of intervention. This may be due to variation in the route of exposures, i.e., 
inhalation versus ingestion. The enterosorption strategy would not be expected to reduce 
exposure from air. Moreover, the structural characteristics of PAH compounds did not 
predict sorption in the gastrointestinal tract; thus, data further confirm the specificity of 
NS for the enterosorption of AFs Although not statistically significant, we observed a 
trend for reduction in 1-OHP levels in participants in the PL group: median reduced 
from 0.66 μmol/mol creatinine at baseline to 0.58 μmol/mol creatinine after 3-months. 
The placebo material used in the intervention study was composed of microcrystalline 
cellulose. Previous work has shown that cellulose (or fiber in general) may alter the 
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entrerohepatic recycling of 1-OHP. For instance, Viau et al. (2004) noted a trend in the 
reduction of urinary 1-OHP excretion in rats fed pyrene and diets containing fiber. 
Additionally, bulk cellulose in the diet was shown to affect the recovery of 1-OHP from 
the urine. Further research is warranted to test cellulose and similar materials for their 
ability to affect toxin adsorption and disposition following oral exposures.  
 In summary, this study illustrates that 1-OHP may be utilized to identify 
populations vulnerable to PAH exposure. A population living in a rural area of Ghana 
frequently exposed to AFs was shown to be highly exposed to PAHs; however, the 
exposure levels were independently distributed. Future research should focus on this 
population to better comprehend the sources of PAH exposure. Additionally, long-term 
biomarkers, like the PAH–albumin adduct could be utilized in prospective studies to 
further investigate associations between PAH exposure and its public health impact. 
Other strategies for the reduction of PAHs besides clay-based enterosorption are 
warranted in this population, as is further investigation to evaluate if the combined 
decrease of exposures to AFs and PAHs may reduce the incidence of liver cancer or 
additional disease. 
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V. ASSESSMENT OF AFLATOXIN AND PAH EXPOSURE BIOMARKERS IN 
A U.S. POPULATION WITH A HIGH INCIDENCE OF HEPATOCELLULAR 
CARCINOMA 
 
5.1 Introduction  
 Hepatocellular carcinoma (HCC) is the most common and widespread form of 
primary liver cancer (Parkin et al. 2001). Approximately 600,000 deaths annually are 
attributed to this malignancy, making HCC the third leading cause of cancer mortality 
worldwide (Kew 2002). Historically, it has been estimated that the majority of HCC 
cases occur in developing countries (Wild and Hall 2000); however, an increased 
incidence of HCC in many developed countries, including the United States, has been 
recognized over the recent decades (El-Serag and Mason 1999). The state of Texas in 
particular has been shown to have the highest HCC mortality rate in the U.S. (Devesa et 
al. 1999). A Hispanic population residing within several zip codes in a community in 
Bexar County, TX has been disproportionately affected by a high incidence of HCC 
(ATSDR 2001). Age-adjusted cancer incidence rates from 2002-2006 (Table XIII) 
demonstrate that Hispanics in Bexar Co. have an increased HCC incidence rate (16.5) 
compared to Hispanics in Texas (10.9); rates per 100,000 (Texas Cancer Registry 2009). 
Notably, the HCC incidence rate for Hispanics living in Bexar Co. is considerably higher 
than all races in Bexar Co. (10.0) and all races in Texas (5.8). Hispanic males in Bexar 
Co. were shown to have the highest incidence rate during this time period at 27.1. Thus 
we were interested in exploring factors that may contribute to HCC in this community. 
  
 
Table XIII. Age-adjusted HCC incidence rates in Texas and Bexar County.   
 
Texas 
All races and ethnicities  Hispanic ethnicity  
Male Female Both Male Female Both 
9.6a  
(9.3 – 9.9) 
2.7 
 (2.5 – 2.8) 
5.8  
(5.7 – 6.0) 
17.1  
(16.2 – 18.0) 
5.8  
(5.3 – 6.2) 
10.9  
(10.4 – 11.4) 
Bexar County 
All races and ethnicities  Hispanic ethnicity  
Male Female Both Male Female Both 
16.3  
(14.8 – 17.8) 
5.0  
(4.3 – 5.8) 
10.0 
(9.2 – 0.8) 
27.1  
(24.2 – 30.2) 
8.4  
(7.0 – 9.9) 
16.5  
(15.0 -18.0) 
 
aRates are per 100,000 and age-adjusted to the 2000 U.S. standard population (95% 
confidence intervals). Date prepared by the Texas Department of State Health 
Services, Cancer Epidemiology and Surveillance Branch, Texas Cancer Registry.   
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 Multiple factors including diet, environment, lifestyle, health status, gender, and 
genetics have been shown to play a role in the etiology of HCC. In section I, this report 
described the importance of dietary AF exposure as a major risk factor for HCC, 
particularly in developing counties. However, numerous individuals in underserved 
populations, even in developed areas, face food insecurity which may necessitate the 
consumption of lower quality foods and thereby increase the likelihood of AF exposure. 
For instance, corn intended for animal feeds (which have much higher allowable AF 
action levels) has been rumored to be consumed by some individuals living in low 
socioeconomic conditions. Furthermore, individuals may be at increased risk for HCC 
due to additional biological factors, namely hepatitis virus and/or concurrent PAH 
exposure. While HBV has been shown to be endemic to parts of the world with high 
HCC cases, the frequency of HBV infection in the U.S. is far lower. Conversely, an 
association between HCV infection and HCC incidence has been demonstrated in the 
U.S., particularly in Texas (Davila et al. 2004). Records from University of Texas (U.T.) 
M.D. Anderson Cancer Center have shown that more than 50% of HCC cases observed 
in Texas could be attributed to HCV infection (Hassan et al. 2002). In recent work, Chen 
et al. (2007) showed AF-albumin adduct levels were associated with advanced liver 
disease in HCV patients in an endemic area in Taiwan, suggesting AFB1 may also 
interact with HCV. Hoque et al. (1999) previously demonstrated the presence of AF-
albumin adducts in a small number of HCC patients (5/5 sera samples) registered at the 
U.T.M.D. Anderson Cancer Center, prompting the question ‘does AFB1 play a role in 
the etiology of HCC in the U.S.?’ While it is established that a viral-chemical interaction 
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exists between hepatitis and AFB1, the possible contribution of AFs in the human diet 
has not yet been assessed in Bexar Co. Due to the disproportionate occurrence of HCC 
observed in an underserved community in this county, an environmental health study 
was conducted as a preliminary survey to assess AF and PAH biomarkers of exposure; 
investigate dietary factors that may contribute to increased AF exposure; and to 
determine other factors that may contribute to increased HCC incidence, namely the 
prevalence of hepatitis infection in the population. Additionally, it was important to 
evaluate biomarker levels as compared to levels in a high risk population (i.e., the 
Ashanti Region of Ghana) as a way of relating domestic and international foodborne and 
environmental exposures. 
5.2 Materials and methods  
5.2.1 Participant recruitment and sample collection  
 Study participants were recruited from three zip codes in the San Antonio 
metropolitan area of Bexar Co., where the incidence of liver cancer has been shown to 
be significantly elevated. These zip codes encompass nearly 11% of Bexar Co.’s 
population, and residents are predominantly Hispanic (90.2%). A total of 186 
participants were recruited at the San Antonio Metropolitan Health District (SAMHD) 
from October 2007 to May 2008. Volunteers (males and females) who qualified as study 
participants met the following criteria: 1) at least 18 years of age and 2) a minimum of 
two years residency (within the last 12 months) in one of the three specified study zip 
codes. The study protocol was approved by the Institutional Review Board at TAMU, 
and all participants were provided written informed consent, as well as oral explanation 
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of the study protocol prior to beginning the study. Upon enrollment, SAMHD public 
health officials administered a questionnaire (in English or Spanish) and collected 
demographic information through in-person interviews. Biological samples, including 
venous blood and urine, were collected, separated, and stored frozen until serum and 
urinary biomarker analyses at the University of Georgia (Athens, GA) and TAMU, 
respectively. Following sample collection, it was noted that two participants did not 
meet the eligibility criteria concerning residency, and data collected from these subjects 
were not included. Thus, a total of 184 participants comprised our study population.   
5.2.2 Chemicals and laboratory analyses 
Authentic AFM1 and 1-OHP standards were purchased from Sigma Chemical 
Co. (St. Louis, MO) and the Midwest Research Institute Chemical Carcinogen Reference 
Standard Repository (Kansas City, MO), respectively. Blood specimens collected from 
study participants were analyzed for complete blood count, HBV surface antigen 
(HBsAg) and anti-HCV antibodies at SAMHD according to standard laboratory 
operating procedures.     
5.2.3 Urinary aflatoxin M1 and 1-hydroxypyrene analyses   
 Urinary AFM1 levels were analyzed using immunoaffinity column purification 
followed by HPLC with fluorescence detection (previously described in detail in Section 
II). Urinary 1-OHP levels were also measured with an HPLC-fluorescence method (as 
described in Section IV). Quantification of AFM1 and 1-OHP were based on peak area 
and retention times as compared to external standards run daily. The limit of detection 
for urinary AFM1 and 1-OHP using these methods was 0.5 pg/ml and 0.25 nmol/L of 
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urine, respectively. Creatinine concentrations were measured at St. Joseph’s Regional 
Health Center Laboratory in order to correct for variations in urine dilution.    
5.2.4 Statistical analysis 
 Median, mean, standard deviation (SD) and detectable range were calculated for 
concentrations of all biomarkers measured. Statistical analyses were done using SPSS 
software version 15.0 (Chicago, IL). For comparisons, student’s t or Wilcoxon rank sum 
tests were used as appropriate to examine differences between biomarker data. Chi-
square tests were performed to examine demographic data and variables assessed by the 
questionnaire. Crude odds ratio estimates for the relationship between various dietary 
factors and AF biomarkers were determined by generating 2 x 2 contingency tables. A p-
value ≤ 0.05 (two-tailed) was considered significant. 
5.3 Results 
5.3.1 Demographics of study participants and hepatitis virus prevalence 
 Table XIV provides the descriptive characteristics and HBV and HCV status in 
the study population. Slightly more than one fourth (26.6%) of the participants were 
male and 73.4% were female. The average participant age was 48 (median: 49; range: 18 
– 83 years). The majority of participants (97.3%) were of Hispanic ethnicity; the 
remaining percentage of the study population (1.1 and 1.6%) was Native American and 
African American, respectively. Serum analysis at SAMHD included screening for 
HBsAg and anti-HCV antibodies. None of the participants were HBsAg+, whereas 7.1% 
(13/184) of the study population was anti-HCV+.  
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Table XIV. Demographic characteristics and HBV/HCV  
serology in Bexar County study participants 
 
Demographic characteristics n (%) 
Gender  
      Male  49 (26.6) 
      Female 135 (73.4) 
Ethnic group  
      Hispanic 179 (97.3) 
      African American 2 (1.1) 
      Native American  3 (1.6) 
Age (year)a 48.3 ± 16.1 
Hepatitis Status  
      HBsAg+b  0 (0.0) 
      Anti-HCV+c 13 (7.1) 
   
 a Data are presented as mean ± SD; bHepatitis B virus 
surface antigen; cAntibodies to hepatitis C virus. 
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5.3.2 Urinary aflatoxin M1 and 1-hydroxypyrene levels  
Urinary AFM1 was detectable in 11.7% of samples analyzed (n = 179) with the 
average level in the detectable group at 223.85 ± 250.56 pg/mg creatinine (median: 
141.53; range: 1.89 – 935.49 pg/mg creatinine). Characteristics described above did not 
differ significantly among the participants in the AF-detectable and non-detectable 
groups. Of the samples available for 1-OHP analysis (n = 160), 51.2% of 125 non-
smokers and 100% of 35 tobacco-smokers had detectable 1-OHP levels with median 
excretion values of 0.01 and 0.17 μmol/mol creatinine, respectively. Moreover, there 
was a significant difference between mean 1-OHP levels measured in non-smokers (0.07 
± 0.13 μmol/mol creatinine) and smokers (0.26 ± 0.33 μmol/mol creatinine) (p < 0.01). 
While a slight lack of concordance between the total number of study participants and 
amount of samples analyzed for AF and PAH biomarkers arose due to unforeseeable 
events during sample collection and transfer, adequate amounts of samples were 
analyzed to validate statistical analysis.   
5.3.3 Food consumption questionnaire 
 A primary aim of the questionnaire administered at SAMHD was to investigate 
dietary factors that could be related to increased AF exposure in the study population. 
Results from questions on food consumption showed that > 98% of participants reported 
that they ate commodities prone to AF-contamination (e.g., corn, nuts, rice and a variety 
of corn/peanut-based foods) at varying frequencies. A large percentage of the population 
(44.8%) consumed corn tortillas frequently (3-14 times per week); the majority (58.2%) 
ate > 2 tortillas at each time of consumption. When food consumption was examined 
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according to urinary AFM1 detection, the amount of corn tortillas (p = 0.009), rice (p = 
0.037), and nuts (p = 0.033) consumed was found to be significantly associated with 
AFM1 excretion (Table XV).  
5.3.4 Comparison of biomarker levels to a high-risk population  
 Biomarker results were compared to levels measured in our well-characterized 
study group in the Ashanti Region of Ghana, which was determined to be a population at 
high risk for both AF and PAH exposures. The distribution of urinary AFM1 and 1-OHP 
in both populations is illustrated in Figure 21. Of the urines collected in Ghana at 
baseline (n = 159), 88.1% had detectable AFM1 levels (section II). The median level of 
the three study groups (49.57 pg/mg creatinine) was significantly higher than the median 
level calculated for 179 participants from Bexar Co. (0.02 pg/mg creatinine) (p < 0.001); 
non-detectable values were assigned half the LOD for statistical analysis. However, the 
median level detected in 140 positive Ghanaian individuals (68.07 pg/mg creatinine) did 
not differ significantly compared to the median level detected in 21 positive participants 
from Bexar Co. (141.53 pg/mg creatinine) (p = 0.707). In samples collected at baseline 
and measured for 1-OHP, the vast majority of Ghanaian participants (98.2% of 113 non-
smokers) had detectable 1-OHP levels (mean ± SD = 0.80 ± 0.68 μmol/mol creatinine).  
This level was significantly higher than the average level detected in non-smokers in 
Bexar Co. (mean ± SD = 0.07 ± 0.13 μmol/mol creatinine) (p < 0.001). Overall, the 
median 1-OHP level for non-smokers observed in Ghana (0.64 μmol/mol creatinine) was 
over 60-times higher than the median level in Bexar Co. (0.01 μmol/mol creatinine).  
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Table XV. Food consumption in Bexar County study population by distribution of 
aflatoxin M1 biomarker.  
 
Aflatoxin M1[n (%)]b  
Type of Food Amount of food consumeda Detectable  Non-detectable 
Corn < ½ cup (1 ear) 2 (10.5) 28 (18.9) 
 ≥ ½ cup (1 ear) 17 (89.5) 120 (81.1) 
Corn tortillas  < 1 tortilla 2 (11.8) 2 (1.4) 
 ≥ 1 tortilla 15 (88.2)* 142 (98.6) 
Corn bread/muffins < 1 piece (muffin) 1 (12.5) 12 (13.0) 
 ≥ 1 piece (muffin) 7 (87.5) 80 (87.0)  
Corn chips < 1 cup (10 chips) 5 (26.3) 44 (30.3) 
 ≥1 cup (10 chips) 14 (73.7) 101 (69.7) 
Rice  < ½ cup 0 (0.0) 31 (19.9) 
 ≥ ½ cup  18 (100.0)*  125 (80.1) 
Peanut butter  < 1 tablespoon 4 (25.0) 17 (19.3) 
 ≥ 1 tablespoon 12 (75.0) 71 (80.7) 
Nuts  < ¼ cup 2 (12.5) 54 (39.7) 
 ≥ ¼ cup 14 (87.5)* 82 (60.3) 
 
aAmount of food consumed at each time of consumption; bNumbers within subgroups 
differ slightly from the total number of samples analyzed for AFM1 due to missing 
responses; *p ≤ 0.05 in comparison of distribution in AFM1-detectable and AFM1-non-
detectable groups in Fisher exact test.      
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Figure 21. Distribution of urinary AFM1 and 1-OHP in study participants in Ghana and the U.S. 
AFM1 levels in study participants from Bexar Co. were detected at a lower percentage (11.7% 
versus 88.1%) and overall level compared to Ghana (a). Additionally, 1-OHP concentrations in 
non-smoking participants from Bexar Co. were detected at a lower percentage (51.2% versus 
98.2%) and level compared to the average level measured in Ghana (b). 
 
 
 
 
 106
5.4 Discussion 
 Areas located between latitudes 40° N and S (which includes the Southern U.S.) 
encompass populations at risk for chronic AF exposure based on suitable temperature, 
humidity and vulnerability of staple commodities for mycotoxin contamination 
(Williams et al. 2004). Since contamination has been reported in foods from Texas and 
surrounding areas such as Mexico, particularly after periods of drought (Torres et al. 
1995; Wood 1992), our primary objective was to assess AF exposure in a predominantly 
Hispanic population in Bexar Co. with an increased incidence of HCC. In this study, 
urinary AFM1 data revealed that the majority of participants had a non-detectable AF 
exposure; this was confirmed by serum AFB1-lysine adduct data, wherein only 20.7% of 
the study population exhibited low levels of detectable AF-adducts (Qian et al. 2009). 
While the correlation between serum and urine AF biomarkers was not significant, 
results indicated that some individuals showed low levels of chronic exposure whereas 
others exhibited low to moderate to high short-term AF exposure. This may be due to the 
differences in half-lives of the two biomarkers. The AF-albumin adduct has a longer in 
vivo half-life reflecting integrated exposures over weeks to months compared to AFM1 
excretion representing recent exposure (i.e., 24 to 48 hours) (Wang et al. 1996b). 
Perhaps in populations with sustained AF exposure at elevated levels it is more likely 
that these biomarkers would have a better correlation, as evidenced previously in Ghana 
(Jolly et al. 2006). While the measurable exposure to AFs at our site in Bexar Co. was 
relatively low, it appeared that an increased consumption of certain food products, 
namely, corn tortillas, nuts and rice, were associated with the detection of AFM1 in the 
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urine. AFs have frequently been detected in corn and groundnuts, and contamination of 
rice has occasionally been reported (Tanaka et al. 2007). Borrud et al. (1989) reported 
that the intake patterns of Mexican Americans demonstrated an adherence to traditional 
Mexican food items, for instance corn tortillas. Several survey studies in Mexico have 
shown corn tortillas to be highly contaminated with AFs (Carvajal et al. 1987; Yepiz and 
Rosas 1994). This commodity may represent a possible source of AF exposure, in 
addition to other corn-based products (e.g., corn masa and tamales and other foods made 
using corn masa) when consumed in high amounts. Further work delineating the source 
of corn (e.g., store bought, home-grown crops, human food grade quality, etc.) may be of 
importance since low socioeconomic conditions may necessitate the use of lower quality 
foods. Importantly, no tolerable daily intake has been set for AFB1, as determined for 
other (less carcinogenic) mycotoxins. However, the FDA has set an action level of 20 
ppb in foods intended for human consumption, which corresponds to ~30 μg AFs/day. 
Assuming a urinary excretion rate of 2 – 5% (Cheng et al. 1997) and an estimated 
metabolic rate of 1500 ml urine/day, daily AFB1 consumption can be calculated from 
AFM1 values. It was estimated that the mean AFM1 excretion in Bexar Co. corresponds 
to an average daily consumption ranging from 9.8 – 24.6 μg AFB1/day. Although the 
estimated average daily AFB1 intake is below 30 μg, individuals in the 75th and 95th 
percentiles may have estimated daily AFB1 consumptions ranging from 15.3 – 38.2 and 
49.2 – 122.9 μg/day, respectively. Thus, human health hazards associated with such AF 
exposure over time cannot be ruled out.  
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When compared to a population in a developing country (i.e., Ghana), findings 
demonstrated that participants in Bexar Co. overall had a lower exposure to AFs. By 
comparison, the percentage and level of AFM1 were lower than those observed in 
baseline samples collected in the Ashanti Region prior to a clinical intervention trial 
(Figure 21a). It can be estimated that the mean AFM1 excretion in this ‘high-risk’ 
population (making the same assumptions as above) corresponds to an average daily 
AFB1 consumption ranging from 17.3 – 43.4 μg/day, with maximum levels reaching as 
high as >547 μg/day. Therefore, it is clear that this population in rural Ghana is at high 
risk for aflatoxicosis. Proper production, storage and processing of foods and effective 
enforcement of regulations contribute to reduced AF exposure in developed countries. 
The lack of food security in sub-Saharan Africa stresses the need for intervention 
strategies to reduce these high level exposures.   
 Of additional concern in Bexar Co. was assessing co-exposure to PAHs, which 
may increase the risk for HCC in the presence of AFs and hepatitis virus infection (Wu 
et al. 2007). Findings from this portion of our study illustrated that all study participants 
classified as tobacco-smokers had detectable levels of urinary 1-OHP, whereas 
approximately half of non-smoking participants did not show a measurable exposure to 
PAHs. Data further demonstrated a significant difference in mean 1-OHP concentrations 
when participants were stratified by smoking status. This is in agreement with previous 
work showing statistically significant increases in 1-OHP excretion in tobacco-smokers 
exposed to background levels of environmental PAHs (Levin et al. 1995; Viau et al. 
1995). Conversely, in our population in Ghana smoking failed to produce any 
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differences in urinary 1-OHP levels, compared to not smoking, indicating a predominant 
environmental PAH exposure. Moreover, 1-OHP levels measured in Bexar Co. were 
considerably lower than those previously recorded in Ghana (Figure 21b). Findings in 
this U.S. population were comparable or lower than those previously recorded for non-
smoking individuals in numerous developed countries (Table III). Overall, results 
suggest that non-tobacco smokers in Bexar Co. are not at high risk for PAH exposure, 
based on this short-term biomarker. Further work assessing chronic PAH exposure may 
be warranted.  
 An additional objective of our environmental health study in Bexar Co. was to 
determine the prevalence of HBV and HCV since hepatitis virus infection clearly 
contributes to the overall burden of HCC. Previous findings from a study in a Texas 
male prison population indicated that inmates who were older, Hispanic, and infected 
with HCV or HBV had elevated rates of both HCC prevalence and mortality 
(Baillargeon et al. 2009). While no participants in our study population were positive for 
the HBsAg, 7.1% were positive for HCV. HBV infection is closely linked to HCC in 
developing countries; however, its impact may be far less in areas of the U.S. where 
HBV vaccination is common. In contrast, the prevalence of HCV is of significant 
importance, especially since no vaccination is currently available. The HCV positivity 
rate in this Bexar Co. community (7.1%) was higher than the overall prevalence in Texas 
reported to be 1.79% (varying from 1.25 – 2.63% across Texas counties) (Yalamanchili 
et al. 2005). Thus, the implementation of biomonitoring and intervention strategies, 
particularly in vulnerable individuals, at high risk for HCV-induced HCC, may play an 
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important role in reducing the overall negative public health impact of dietary AF 
exposure.  
 In conclusion, results from our environmental health study showed a significant 
association of increased consumption of certain foods and the excretion of AFM1 in a 
minority population in Texas. In addition, the HCV positivity rate is comparatively high 
in this community and warrants considerable attention. Biomarkers measured in this 
study reflect current exposures to AFs and PAHs. The development of HCC is a 
multistage process that involves many factors over an extended period of time. The 
increased incidence of liver cancer observed in Bexar Co. presumably was initiated by 
exposures occurring 20-30 years ago. The primary goal of this pilot study was to gain 
insight into the current public health of this underserved community and gather 
information to support further exploration of potential factors that can contribute HCC 
risk. A limitation of our study was the uneven recruitment of females due to the lack of 
male participation. Since the incidence of HCC in Hispanic males in Bexar Co. has been 
shown to be significantly elevated, further work is warranted to reflect the participant 
demographic that is apparently the most vulnerable to HCC development. Additionally, 
proper control populations in the U.S. are needed to better elucidate the role of AFs in 
populations at risk for HCC. 
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VI. SUMMARY 
 
Chronic exposure to dietary AFs is a major risk factor for human hepatocellular 
carcinoma development. At high levels, AFs can cause disease (aflatoxicosis) and death. 
Therefore, the significant negative health impact of AFs necessitates safe and effective 
intervention strategies to reduce biological exposure in humans. This has been especially 
apparent in developing countries and the poorest populations like those in sub-Saharan 
Africa where the likelihood and resulting impact of exposure is elevated. The recent 
outbreak in Kenya, which resulted in 125 deaths following acute exposure to high levels 
of AFs, reaffirmed AF exposure as a critical issue requiring attention. NovaSil (NS) 
clay, a dioctahedral smectite, has been shown to prevent aflatoxicosis in multiple animal 
species by preferentially binding AFs in the gastrointestinal tract and reducing toxin 
bioavailability. Given the safety of NS, demonstrated in a variety of animal models and 
in a short-term human study, a Phase IIa clinical intervention trial was conducted in the 
Ashanti Region of Ghana. Previous biomarker data showed this population was at risk 
for aflatoxicosis based on high levels of aflatoxin M1 (AFM1) in the urine and aflatoxin 
B1-lysine albumin adducts in the blood of study participants. Thus, the specific aims of 
this study were to evaluate the ability of NS to reduce AF biomarkers of exposure 
(objective 1) and to investigate interactions of NS with important nutrient minerals 
(objective 2) following intervention. After 3-months of NS capsule ingestion at the high 
dose level, median AFM1 levels were significantly reduced (up to 58%) when compared 
to levels in the placebo group. In addition, there was a concurrent reduction in AF-
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albumin adduct levels after 3-month intervention at this minimally effective dose level. 
This was the first study to show NS can effectively reduce AF exposure from 
contaminated diets of humans, signifying its potential use in populations at high risk for 
aflatoxicosis. Furthermore, no significant differences were found in levels of nutrient 
minerals between NS-treated and placebo groups after clinical intervention, suggesting 
NS can be used to effectively sorb dietary AFs without affecting serum concentrations of 
important nutrient minerals. Of the 30 nutrient and non-nutrient minerals measured, only 
levels of serum strontium (Sr), a non-nutrient mineral, were affected by NS dietary 
inclusion. Results from a clinical trial in osteoporosis patients indicated Sr 
supplementation, at a level over 150-times higher than the estimated amount of Sr that 
could be supplied from NS clay, did not produce any adverse effects in study 
participants. Therefore, findings do not suggest physiological levels of Sr would be 
significant enough to yield a negative effect from this low level in NS clay. In fact, Sr 
could be considered a potential benefit in the diet since it may act like Ca in regards to 
its concentration in the bone. Since NS is a natural product, considerable efforts were 
made to ensure its purity prior to the intervention. For instance, all potential 
contaminants (i.e., dioxins and heavy metals) were either below the LOD or present in 
the high dose at levels considerably lower than the current WHO/JECFA standards. In 
the future, the purity and batch-to-batch consistency of the test agent should continue to 
be closely monitored. It is also important that any strategy for the reduction of AFs is 
both sustainable and culturally acceptable. NS meets both of these criteria, as it is 
common practice in many parts of sub-Saharan Africa, including Ghana, for humans to 
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consume ‘edible’ clays. As a rationale to affirm sustainability of this strategy, work is 
ongoing to identify clays in Ghana similar to NS for subsequent human studies. Overall, 
findings provide the basis for future long-term studies to evaluate the safety and efficacy 
of NS as an enterosorbent therapy for acute AF exposure and for the prevention of 
chronic AF-induced disease or cancer. In the future, inclusion of NS clay in the diet may 
become a readily available technology that constitutes an economically feasible therapy 
for use in developing countries to possibly save human lives by reducing disease and 
preventing death in outbreak situations. 
Of additional concern were other environmental carcinogen exposures that could 
contribute to or enhance AF-induced disease. Recent epidemiological data indicated an 
increased HCC risk was found among participants co-exposed to high levels of AFs and 
polycyclic aromatic hydrocarbons (PAHs). It was postulated that our study population in 
Ghana (at risk for aflatoxicosis) may be concurrently exposed to PAHs from a variety of 
environmental sources. Although sources of PAH exposure may be familiarized with 
images of industrial manufacturing or polluted urban air, there is a great opportunity for 
exposure in rural areas of developing countries since approximately 90% of these 
populations (totaling over 50% of the world populace) burn biomass as an energy 
source. Subsequently, a third objective of this study was to determine PAH exposure 
(previously unknown in this rural population) by measuring 1-hydroxypyrene (1-OHP) 
in urine samples collected from the NS intervention study. Results showed participants 
were significantly exposed to PAHs based on the presence of 1-OHP in the majority of 
urines collected (98.9%) and high levels measured at baseline and 3-months (median 
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excretion values were 0.64 and 0.69 μmol/mol creatinine, respectively). The potential 
effect of enterosorption on the bioavailability of PAHs from the gastrointestinal tract had 
yet to be investigated. Thus, a supplementary objective was to compare 1-OHP values in 
NS and placebo groups. Findings demonstrated treatment with NS clay had no effect on 
1-OHP levels, further confirming the preferential binding of AFs by NS. A trend for the 
reduction in median 1-OHP levels in the placebo group was observed following 3-month 
intervention. However, since the placebo consisted of cellulose, i.e., bulk fiber, the effect 
was likely due to the alteration in enterohepatic recycling of 1-OHP. Furthermore, the 
cooking culture of this population implied a predominant exposure from preparing foods 
and socializing by fires; thus clay-based enterosorption would clearly not have an effect 
on PAH exposure via inhalation routes. Future strategies to reduce exposure from this 
route would be of great benefit. For instance, in a previous study in Mexico, researchers 
showed 1-OHP levels were significantly reduced following an intervention aimed at 
reducing indoor smoke exposure by introducing new stoves with metal chimneys that 
expelled smoke outdoors (Torres-Dosal et al. 2008). Furthermore, cleaner cook stoves 
implemented in homes in India have shown great promise to reduce human exposure to 
contaminants in smoke, i.e., PAHs (Adler 2010). Likewise, an initiative in Ghana to 
employ cleaner cook stoves, mainly powered by propane, is being considered by the 
Ghanaian government. The success of this initiative, particularly in remote rural areas, 
like the Ejura-Sekyedumase district, will depend on the cost to the consumer and cultural 
acceptance of new cooking methods to ensure long-term viability. Overall, biomarker 
data from this study illustrated a population at high risk for aflatoxicosis was at a parallel 
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risk for PAH exposure. Further investigation is warranted to evaluate if the combined 
decrease of exposures to AFs and PAHs may reduce the incidence of liver cancer or 
additional disease. 
  While it has been reported that the majority of liver carcinomas occur in 
developing countries, the incidence of HCC in the U.S. has increased over the recent 
decades. In order to compare domestic and international foodborne and environmental 
exposures, an environmental health survey was conducted in Bexar County, Texas 
(objective 4) in a Hispanic community shown to have an elevated incidence of HCC. In 
this study, the incidence and level of AF and PAH exposures were lower than data 
observed in our study population in Ghana; however, some participants were exposed to 
moderate to high levels of dietary AFs, based on elevated AFM1 values. Additionally, 
the increased consumption of certain foods prone to AF contamination (i.e., corn 
tortillas, nuts, and rice) was associated with AFM1 excretion. Thus, some individuals 
may be more vulnerable to exposure and associated interactions with other biological 
factors, namely HCV. The positively rate for HCV in this population was considerably 
higher than recorded prevalence rates in other areas of Texas. It is well-established that 
HBV infection increases the carcinogenic potency of AFB1 (reported to be ~30 times 
higher in HBsAg+ individuals versus HBsAg- individuals). A correlation between AF 
exposure and advanced liver disease has also been demonstrated in HCV positive 
individuals. Therefore, reducing AF exposure in populations with a high prevalence of 
HBV or HCV may have a substantial impact on reducing liver disease and HCC rates. 
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In summary, the ability for researchers to monitor and quantify human exposure 
to carcinogens stems from the development and validation of chemical-specific 
biomarkers. An important application of biomonitoring can be to identify populations at 
risk for environmental exposures, as shown in this work. In regards to the further 
advancement of the field of exposure science, it has been suggested that the human 
‘exposome’ needs to be sequenced to fully understand the extent and effect of human 
exposures. The application of this ‘omics’ discipline, arising from the sequencing of the 
human genome published nearly a decade ago, may provide a breath of knowledge to aid 
in further identifying what exposures exist and possibly means to negate them. Overall, 
from basic research stemming from the discovery of AFs to more recent epidemiological 
work strengthening correlations between exposures and human health effects, AF 
research has become a model for how fundamental toxicological science can translate 
into public health protection.  
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